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I. INTRODUCTION
WHEN THE MEDICAID PROGRAM was enacted in
1965,1 the original statutory scheme envisioned a rapid transi-
tion to a "comprehensive" scope of services for broad categories
of individuals. 2 This "comprehensiveness" requirement was
added to the Social Security Act "in order to encourage the
continued development in the States of a broadened and more
liberalized medical assistance program so that all persons who
met the State's test of need... [would] receive the medical care
which they need by 1975." 3
In 1969, the "comprehensiveness" requirement was recon-
sidered by Congress. In response to cries of impoverishment
from the various states, 4 the Senate Finance Committee recom-
mended indefinite suspension of this requirement.5 However,
the Finance Committee recommendation was rejected in favor
of a compromise whereby section 1903(e) was suspended in op-
1 Social Security Amendments of 1965, Pub. L. No. 89-97, §§ 1901-05, 79
Stat. 286, 343-52 (1965).
2 Social Security Act of 1965, Pub. L. No. 89-97, § 1903(e), 79 Stat. 286,
350-51 (1966), repealed by Social Security Amendments of 1972, Pub. L. No. 92-
603, § 230, 86 Stat. 1410 (1972). Section 1903(e) provided as follows:
The Secretary shall not make payments under the preceding provisions of
this section to any State unless the State makes a satisfactory showing that
it is making efforts in the direction of broadening the scope of the care and
services made available under the plan and in the direction of liberalizing
the eligibility requirements for medical assistance, with a view toward fur-
nishing by July 1, 1975, comprehensive care and services to substantially
all individuals who meet the plan's eligibility standards with respect to in-
come and resources, including services to enable such individuals to attain
or retain independence or self-care.
42 U.S.C. § 1396b (1965), reprinted in 1969 U.S.C.C.A.N. 1077, 1080.
The federal guidelines interpreting this section stated that, "[c]omprehensive
care includes all preventive, diagnostic, curative and rehabilitative services or goods
furnished, prescribed or ordered by a recognized practitioner of the healing arts
within the scope of his practice." U.S. DEP'T OF HEALTH, EDUC. & WELFARE,
HANDBOOK OF PUBLIC ASSISTANCE ADMINISTRATION, SUPPLEMENT D: MEDICAL
ASSISTANCE PROGRAMS D-5142 (1966). The "comprehensiveness" requirement was
repealed by section 230 of the Social Security Amendments of 1972, Pub. L. No. 92-
603, 86 Stat. 1410 (1972).
3 Report of Ways and Means Committee on the Social Security Amendments
of 1965, H.R. REp. No. 89-213, at 74 (1965).
4 See S. REP. No. 91-222 (1969), reprinted in 1969 U.S.C.C.A.N. 1077, 108 1-
82 (reporting comments of State Governors).5 See id.
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eration for two years (until July 1, 1971),6 and the time within
which the participating states would be required to achieve a
comprehensive medical assistance program was extended for
two years (until July 1, 1977).
In 1971, New York became one of the first states to signifi-
cantly cut back benefits under the Medicaid program. After an
order was issued temporarily restraining the proposed cutbacks
because of the failure of the State to obtain prior approval from
the Secretary of Health, Education, and Welfare,9 the State ob-
6 See Pub. L. No. 91-56, § 2(b), 83 Stat. 99, 99 (1969). "The provisions of
section 1903(e) of the Social Security Act shall not apply for any period prior to July
1, 1971. In performing his functions under title XIX of the Social Security Act, the
Secretary of Health, Education and Welfare shall issue regulations and give advice to
the States consistent with the preceding sentence." Id.
7 Section 2(a) of Pub. L. No. 91-56, 83 Stat. 99 (1969), delayed the effective
date of section 1903(e) of the Social Security Act by substituting "1977" for "1975"
in subsection (e). See id.
8 On April 14, 1971, New York State amended its Social Services Law by
enacting Chapters 113 and 131 of the Laws of 1971, to be effective May 15, 1971.
As described by U.S. District Judge Cooper:
The new law sought to significantly and drastically infringe upon the avail-
ability of medical assistance by reducing the amount of income and re-
sources an individual may have and hold and still remain eligible for
Medicaid. Additionally, many medical services previously supplied would
be eliminated for that category of recipients described as "medically
needy," i.e. those individuals with incomes and resources above the cash
public assistance level but below the level necessary to purchase such es-
sential medical services [such as dental care, prescribed drugs, and eye-
glasses].
Bass v. Richardson, 338 F. Supp. 478,481 (S.D.N.Y. 1971).
Over the next 20 years, state after state would alternately cutback and expand
their Medicaid programs to deal with projected budget deficits, often without real
thought of the true financial consequences of cutbacks and their impact on the health
of Medicaid beneficiaries. See David F. Chavkin, Florida Medicaid Reform: Less is
Not Always Cheaper, 14 CLEARINGHOUSE RaV. 324 (1980) (describing the cost-
inefficiency of cutbacks implemented in Florida in the 1970s).
9 In Bass v. Rockefeller, 331 F. Supp. 945 (S.D.N.Y. 1971), Judge Tenney
ruled that prior approval of the Secretary of Health, Education, and Welfare was an
absolute prerequisite to amendments effecting state plan reductions under section
1902(d) of the Social Security Act, 42 U.S.C. § 1396a(d). Section 1902(d) was added
to the Social Security Act by section 2(d) of Pub. L. No. 91-56, effective August 9,
1969. Section 1902(d) of the Social Security Act provided as follows:
Whenever any State desires modification of the State plan for medical as-
sistance so as to reduce the scope or extent of the care and services pro-
vided as medical assistance under such plan, or to terminate any of such
care and services, the Secretary shall, upon application of the State, ap-
prove any such modification if the Governor of such State certifies to the
Secretary that -
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tained approval from the Secretary and pursued the cutbacks.
The approval by the Secretary and the underlying cutbacks were
then challenged as violative of section 1902(d) (the "mainte-
nance of effort" requirement) and section 1903(e) (the
"comprehensiveness" requirement). 10
(1) the average quarterly amount of non-Federal funds expended in pro-
viding medical assistance under the plan for any consecutive four-
quarter period after the quarter in which such modification takes ef-
fect will not be less than the average quarterly amount of such funds
expended in providing such assistance for the four-quarter period
which immediately precedes the quarter in which such modification is
to become effective,
(2) the State is fully complying with the provisions of its State plan (re-
lating to control of utilization and costs of services) which are in-
cluded therein pursuant to the requirements of subsection (a) (30), and
(3) the modification is not made for the purpose of increasing the stan-
dard or other formula for determining payments for those types of
care or services which, after such modification, are provided under the
State plan,
and if the Secretary finds that the State is complying with the provisions of
its State plan referred to in clause (2); except that nothing in this subsection
shall be construed to authorize any modification in the State plan of any
State which would terminate the care or services required to be included
pursuant to subsection (a) (13) [sic] Any increase in the formula or other
standard for determining payments for those types of care or services
which, after such modification, are provided under the State plan shall be
made only after approval by the Secretary.
Social Security Act of 1969, Pub. L. No. 91-56, § 2(d). Section 1902(d) was shortly
thereafter repealed by section 231 of the Social Security Amendments of 1972, Pub.
L. No. 92-603 (1972). Bass v. Rockefeller was subsequently dismissed as moot when
the Secretary approved the cutback. See Bass v. Richardson, 338 F. Supp. 478, 481-
82 (S.D.N.Y. 1971) (describing the prior history of the dispute).
1t The "maintenance of effort" requirement provided as follows:
(d) Whenever any State desires a modification of the State plan for medical
assistance so as to reduce the scope or extent of the care and services pro-
vided as medical assistance under such plan, or to terminate any of such
care and services, the Secretary shall, upon application of the State, ap-
prove any such modification if the Governor of such State certifies to the
Secretary that -
(1) the average quarterly amount of non-Federal funds expended in pro-
viding medical assistance under the plan for any consecutive four-
quarter period after the quarter in which such modification takes effect
will not be less than the average quarterly amount of such funds ex-
pended in providing such assistance for the four-quarter period which
immediately precedes the quarter in which such modification is to be-
come effective ....
42 U.S.C. § 1396a(d)(1), added by Pub. L. No. 91-56, § 2(d) (1969), repealed by
Social Security Amendments of 1972, Pub. L. No. 92-603, § 231 (1972).
[Vol. 11:189
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By the time that the case was heard by the district judge
after July 1, 1971, section 1903(e) was effective once again.11
As noted by Judge Cooper:
It has now come to pass that the Secretary must make
two independent findings before any reduced payments
can be effected. He must first find that the State "is fully
complying with the provisions of its State plan" in §
1902(d)(2); secondly, and before he may give approval,
he must find that the State's showing is "satisfactory"
that any such reduction, if effected, is fully in accor-
dance with § 1903(e). Each finding is reviewable, and
each finding was, in all probability, unwarranted in this
case.
12
The burden imposed by section 1903(e), the
"comprehensiveness" requirement, proved to be fatal to the
State's case.13 As noted by the Court, "[p]articularly in the case
of a reduction, the State has a heavy burden under § 1903(e) to
show that it in fact is making efforts to broaden the scope of
care and services and to achieve the comprehensive goals of
substantially full coverage."14 The Court then concluded that
the State of New York had not met that burden:
The record is absolutely barren of facts to indicate in
any way that New York State has any intention by legal
commitments or other means of restoring these cutbacks
before July 1, 1977 . . . .Even the most solemn of
promises is insufficient here without precise legislature
commitment of at least sources of funds, if not the ac-
tual funds. 15
It should not have been surprising that section 1903(e)
would be the subject of future congressional action. As costs of
the Medicaid program increased along with health care costs
"1 See Social Security Act of 1965, Pub. L. No. 89-97, § 1903(e), 79 Stat. 286,
350-51 (1966), repealed by Social Security Amendments of 1972, Pub. L. No. 92-
603, § 230, 86 Stat. 1329, 1410 (1973) (referencing § 1903(e) of the Social Security
Act of 1965).12 Bass v. Richardson, 338 F. Supp. 478,485 (S.D.N.Y. 1971).
13 See id. at 489.
14 Id. at 485 (citation omitted).
' Id. at 489.
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generally, state budgets were increasingly strained. 16 In 1972,
only a year after the decision in Bass v. Richardson, section
1903(e) was repealed completely, effective October 30, 1972.17
After being suspended and delayed, the requirement of move-
ment towards comprehensive care and services in state Medi-
caid programs was eliminated.
Since that date, we have seen an increasing trend on the
part of Congress to turn Medicaid from a categorical grant pro-
gram into a block grant program. 18 Under a block grant model,
state administration would be subject to minimal supervision by
the federal government and wide variation in spending priorities
would likely be reflected in state plans. By contrast, in the ex-
isting categorical grant program model, states complain of mi-
cro-management by the federal government and of federal bar-
riers to state innovation. 19 It is against this political and legal
16 Despite the repeal of section 1903(e) and its "comprehensiveness" require-
ment in 1972, the problem of skyrocketing Medicaid costs would only increase in
severity in the years ahead. As the total number of Medicaid recipients increased
marginally from 17.6 million to 21.6 million from 1972 to 1980, the total payments
made to health care providers nearly quadrupled from $6.3 million to $23.3 million.
U.S. DEP'T or HEALTH & HUM. SERV., HEALTH UNrTED STATES: 1999, table 137 at
310 (1999).
17 See Social Security Amendments of 1972, Pub. L. No. 92-603, § 230, 86
Stat. 1329, 1410 (1972).
IS The congressional efforts were exemplified in several bills. See Welfare
and Medicaid Responsibility Exchange Act of 1995, S. 140, 1 04 th Cong. (1995)
(noting that bill was sponsored and introduced by Sen. Kassebaum on Jan. 4, 1995
"[t]o shift financial responsibility for providing welfare assistance to the States and
shift financial responsibility for providing medical assistance under title XIX of the
Social Security Act to the Federal Government, and for other purposes"); see also
Medicaid Flexibility Act of 1995, S. 844, 104th Cong. (1995) (sponsored and intro-
duced by Sen. Ashcroft on May 23, 1995 "[t]o replace the Medicaid Program with a
block grant to the States, and for other purposes"); Balanced Budget Reconciliation
Act of 1995, H.R. 2491, 104th Cong. (1995) (proposing to transform the Medicaid
program into a new Medigrant program in Title VII of the Act; legislation was spon-
sored and introduced by Rep. Kasich on Oct. 17, 1995); 141 CONG. REc. H8308,
H8308 (1995) (providing "[a] bill to amend the Public Health Service Act and the
Social Security Act to improve the access of rural residents to quality health care by
consolidating various categorical programs into a single program of grants to the
States, and for other purposes") (sponsored and introduced by Rep. Williams); Wel-
fare and Medicaid Reform Act of 1996, H.R. 3734, 104th Cong. (1996) (sponsored
and introduced by Rep. Kasich on June 27, 1996 to terminate the existing Social Se-
curity Act welfare and medical assistance grant-in-aid programs and establish block
grants for temporary welfare assistance and medical assistance).
19 See The Federalism Act of 1999: Hearings on H.R. 2245 Before the Sub-
comm. on Nat'l Econ. Growth, Natural Resources, and Regulatory Affairs of the
House Comm. on Gov't Reform, 10 6 h Cong. 65-75 (1999) (prepared statement of
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backdrop that the recent dispute regarding Medicaid coverage of
Viagra has played out.
II. THE ADVENT OF VIAGRA20
Erectile dysfunction 21 affects approximately five percent of
all men at the age of 40.22 Prevalence increases with age and 15
percent to 25 percent of men 65 years of age and older are af-
fected.23 Moreover, the prevalence of erectile dysfunction cor-
relates directly with several age-related diseases.
24
Prior to the advent of Viagra, erectile dysfunction was
managed with mixed success through psychotherapy,25 intra-
cavernosal injection therapy, 26 vacuum constriction devices,27
Raymond C. Scheppach, Executive Director, on behalf of the National Governors'
Ass'n). However, the frequent claim that states are laboratories for health care reform
impeded by the federal government has its detractors. See Fernando R. Laguarda,
Note, Federalism Myth: States as Laboratories of Health Care Reform, 82 GEO. L.J.
159 (1993).
20 See generally AMERICAN PHARMACEUTICAL ASS'N, NEW PRODUCT
BULLETIN: VIAGRA TM (SILDENAFIL) (1998).
21 The term "erectile dysfunction" refers to the consistent inability to achieve
or maintain an erection sufficient for satisfactory sexual performance. See NIH Con-
sensus Development Panel on Impotence, Impotence, 270 JAMA 83, 83 (1993). See
generally John D. McConnell & Jean D. Wilson, Impotence, in HARRISON'S
PRI IPLES Or- INTERNAL MEDICINE 286-89 (Anthony S. Fauci et.al. eds., 14th ed.
1998). 1 See NIH Consensus Development Panel on Impotence, supra note 21, at
84.
2- See id.
24 See Henry A. Feldman et aL, Impotence and Its Medical and Psychosocial
Correlates: Results of the Massachusetts Male Aging Study, 151 J. UROLOGY 54
(1994) (finding that certain medical conditions and diseases are significantly associ-
ated with prevalence of erectile dysfunction in older men).
25 See NIH Consensus Development Panel on Impotence, supra note 21, at
87; see also A.J. Riley & L. Athanasiadis, Impotence and Its Non-Surgical Manage-
menit, 51 BRrr. J. CutrIcAL PRAc. 99 (1997) (discussing sex therapy as the psycho-
therapeutic approach of choice).
26 The term "intracavemosal injection therapy" refers to the injection of a
vasoactive agent into the corpora cavernosa of the penis to produce penile erection.
See Luis Garcia-Reboll et al., Drugs for the Treatment of hnpotence, 11 DRUGs &
AGING 140, 140-41 (1997); Drogo IC. Montague et al., Clinical Guidelines Panel on
Erectile Dysfiction: Summary Report on the Treatment of Organic Erectile Dys-
function, 156 J. UROLOGY 2007 (1996) (outlining effective treatments for impotence);
Douglas M. Dewire, Evaluation and Treatment of Erectile Dysfunction, 53 AM. FAM.
PHYSICIAN 2101, 2105 (1996).
27 Vacuum constriction devices are hollow cylinders with a movable rubber
ring or band and a pump mechanism. The cylinder is lubricated and placed over the
penis, creating an airtight seal. The pump is used to generate a vacuum inside the
20011
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hormonal therapy, 28 penile prostheses,29 and other therapies. 30
Viagra31 was the first oral therapy to be approved for the treat-
ment of male erectile dysfunction. 32 It was approved by the
cylinder and the negative pressure results in increased arterial blood flow and penile
erection. The rubber ring is then rolled from the cylinder to the base of the penis.
Blood is trapped within the penis by the constriction of the rubber ring, producing a
rigid erection. See Dewire, supra note 26, at 2105; K. Allen Greiner & John W. Wei-
gel, Erectile Dysfunction, 54 AM. Fmis. PhYSIciAN 1675, 1680 (1996).
28 Androgen replacement therapy may be indicated if erectile dysfunction is
the result of primary or secondary testicular failure, both of which are characterized
by low serum testosterone concentrations. See NIH Consensus Development Panel on
Impotence, supra note 21, at 87; Dewire, supra note 26, at 2104.
29 A semi-rigid, malleable or inflatable prosthetic device may be surgically
implanted in the penis. See Greiner & Weigel, supra note 27, at 1681; see also Mon-
tague et al., supra note 26, at 2008.
" Other therapies include vascular surgery, intraurethral administration of
alprostadil formulated as suppositories, and topical administration of alprostadil,
papaverine, nitroglycerin, or minoxidil. See generally Harin Padma-Nathan et al.,
Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil, 336
NEW ENG. J. MED. 1 (1997); Greiner & Weigel supra note 27, at 1680-81; PHY-
Sicms' DESK REFERENCE 2381-84, 2418-21, 3082, 3143-46 (David W. Sifton ed.,
5 4 th ed. 2000); Edward D. Kim & Larry . Lipshultz, Advances in the Treatment of
Organic Erectile Dysfitnction, Hosp. PRAC., Apr. 15, 1997, at 101.
31 Viagra is the trademark of Pfizer, Inc. Viagra is the citrate salt of sildenafil,
a selective inhibitor of cyclic guanosine monophosphate (CGMP)-specific phos-
phodiesterase type 5 (PDE5). See Pfizer, Inc., U.S. Product Prescribing Information
(visited July 8, 1999) <http:lwww.pfizer.comlhmllpi's/viagrapi.html>. In addition to
the active ingredient (sildenafil citrate), each tablet contains the following inactive
ingredients: microcrystalline cellulose, anhydrous dibasic calcium phosphate, cro-
searmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, titanium
dioxide, lactose, tracetin, and FD & C Blue #2 aluminum lake. See id.
32 Sexual stimulation is still required for an erection because sildenafil does
not have a direct relaxant effect on smooth muscle. In the absence of sexual stimula-
tion, sildenafil has no effect. See Viagracom (last modified Jan. 2000)
<http:llwww.viagra.comlprofessionaslpro-pack-insert.asp> (describing the nature,
pharmacology, effects, and risks of Viagra as indicated in the package insert). This
point is emphasized in the Patient Summary of Information About Viagra published
by Pfizer, Inc. In answering the question, "What is Viagra?", the Patient Summary
explains:
VIAGRA is a pill used to treat erectile dysfunction (impotence) in men. It
can help many men who have erectile dysfunction get and keep an erection
when they become sexually excited (stimulated). You will not get an erec-
tion just by taking this medicine. VIAGRA helps a man with erectile dys-
function get an erection only when he is sexually excited.
Pfizer Inc., Patient Summaty of Information About Viagra ® (sildenafil citrate) Tab-
lets (visited July 8, 1999) <http:llwww.viagra.comlconsumerprod_info.htm>. It will
hardly be the last prescription medication for treatment of erectile dysfunction. See
Geoffrey Cowley, Looking Beyond Viagra, NEWSWEEK (Japan-Korea), Apr. 24, 2000,
at 50 (describing progress towards marketing of additional anti-impotence drugs).
[Vol. I 1:189
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Food and Drug Administration on March 27, 199833 and has
been an enormously successful product for Pfizer.34 That suc-
cess reflects the pent-up demand for a simple treatment of a
condition that not only affects millions of men and their part-
ners,35 but one that goes to the core identity of many men. The
stage was set for a confrontation between the states and the fed-
eral government over coverage of Viagra in the major health
insurance program for the poor--the Medicaid program.
37
.3 See Determination for Regulatory Review Period for Purposes of Patent
Exclusion; Viagra, 64 Fed. Reg. 4115 (1999) (establishing the regulatory review pe-
riod for purposes of patent extension for Viagra).
Viagra's worldwide sales for the first quarter of 1999 were $193 million.
First launched in the U.S. in April 1998, more than 9 million prescriptions had been
written for more than 4 million patients in the U.S. alone. Viagra had been approved
in 77 countries and launched in 62 through the end of the quarter. See Pfizer Inc.,
2000 First Quarter Earnings Release: Pfizer isT Quarter Total Revenues of $3,927
Million Up by 29 Percent (issued Apr. 15, 1999) (visited Oct. 10, 2000)
<http://www.pfizer.com/pfizerincinvesting/annual/earnings/l1999Qleampr.htnl>.
For a discussion of the development and introduction of Viagra, see Peter Carlson,
Potent Medicine: A Year Ago, Viagra Hit the Shelves and the Earth Moved. Well,
Sort of, WASH. POST, Mar. 26, 1999, at C1 (describing success of Viagra from a pa-
tient's and Pfizer's standpoints).
35 By the first quarter of 1999, one in three U.S. doctors had written a pre-
scription for Viagra, "including over 95 percent of urologists, 70 percent of cardiolo-
gists and half of all primary care physicians." Pfizer 2000 First Quarter Earnings
Release, supra note 34.
.6 In his testimony before the Pennsylvania House Health and Human Serv-
ices Committee, Dr. Mike Magee, Senior Medical Advisor for Pfizer, described "sto-
ries of men who had downwardly spiraled as a result of erectile dysfunction; had
marital difficulties, had problems on the job, had depression, had this condition affect
their lives in a significant way." Hearing on Access to Pharmaceutical Services in the
Medical Assistance Program: Hearings Before the Pennsylvania House Comm. on
Health & Hum. Se,. (Oct. 8, 1998) at 9 (copy on file with author) [hereinafter Tran-
script of Pennsylvania Hearing] (statement of Dr. Mike Magee, Pfizer Senior Medical
Advisor). Among the witnesses were Dr. Mike Magee, Senior Medical Advisor for
Pfizer, and William Stayton, President of the American Association of Sex Educa-
tors, Counselors and Therapists and Adjunct Professor, University of Pennsylvania.
See id. It is hardly a magic bullet for every instance of sexual dysfunction in an inti-
mate relationship, however. See Lynne Lamberg, New Drug for Erectile Dysfunction
Boonfor Many, "Viagravation"for Some, 280 JAMA 867 (1998).
37 Viagra is not the first anti-impotence treatment to raise the specter of wide-
spread state noncompliance with Federal Medicaid standards. Starting in 1996,
Alaska, Delaware, Idaho, Kentucky, North Carolina, South Dakota, Washington, and
Wyoming excluded Medicaid coverage of Caverject. See Idaho May Violate Federal
Law for Denying Impotence Drug, IDAHO STATESMAN, Jan. 2, 1998, at 5b. States
argued unsuccessfully that Caverject came within the exclusion of drugs to treat in-
fertility. See id However, in language evocative of the dispute to come over Medi-
caid coverage of Viagra, the Health Care Financing Administration notified states
that Caverject is not a fertility drug and that states must provide Medicaid coverage.
2001]
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I. MEDICAID COVERAGE OF PRESCRIPTION
DRUGS
Since the enactment of the Medicaid program in 1965, pre-
scribed drugs have been a type of "medical assistance" 38 for
which federal financial participation is available.39 However,
although prescribed drugs have been included within the Medi-
caid program, they have not been treated in the same way as
physician services, hospital services, and many other forms of
medical care.
The federal Medicaid statute distinguishes between "re-
quired" services that must be included in approved state plans
for at least some categories of eligible beneficiaries and "op-
tional" services that may be included. Despite the critical role
Health Care Financing Admin., STATE MEDIcAID DRUG REBATE PROGRAM RELEASE
55 (circa 1997-98) (on file with author); see also Idaho May Violate Federal Law For
Denying Impotence Drug, supra.
38 The term "medical assistance" is a term of art in the Medicaid program
used to describe those goods and services for which federal financial participation is
available when provided to eligible individuals. For example, section 1903(a)(1) of
the Social Security Act provides that, "[firom the sums appropriated therefor, the
Seretary ... shall pay to each State which has a plan approved under this subchapter
... (1) an amount equal to the Federal medical assistance percentage... of the total
amount expended during such quarter as medical assistance under the State plan ...
42 U.S.C. § 1396b(a)(1) (1994) (emphasis added). Section 1905(a) of the Social Se-
curity Act provides as follows: "The term 'medical assistance' means payment of part
or all of the cost of the following care and services... (12) prescribed drugs, den-
tures, and prosthetic devices; and eyeglasses prescribed by a physician skilled in
diseases of the eye or by an optometrist, whichever the individual may select....
42 U.S.C. § 1396d(a)(12) (1994).
39 Pursuant to section 1905(b) of the Social Security Act, federal financial
participation varies inversely with the per capita income in the state. Poorer states
receive a higher federal matching rate (which cannot exceed 83 percent) and wealth-
ier states receive a lower federal matching rate (which cannot be less than 50 per-
cent). See 42 U.S.C. § 1396b(a), (b) (1994).
40 Section 1902(a) of the Social Security Act provides that, "[a] State plan for
medical assistance must - (10) provide - (A) for making medical assistance avail-
able, including at least the care and services listed in paragraphs (1) through (5), (17)
and (21) of section 1396d(a) of this title, to [specified classes of beneficiaries] .... "
42 U.S.C. § 1396a(a)(10) (1994 & Supp. m1 1998). The so-called "required" care and
services listed in these designated paragraphs include inpatient hospital services;
outpatient hospital services; rural health clinic services; federally-qualified health
center services; laboratory and x-ray services; nursing facility services; early and
periodic screening, diagnostic, and treatment services; family planning services and
supplies; physicians' services; medical and surgical services furnished by a dentist;
services furnished by a nurse-midwife; and services furnished by a certified pediatric
nurse practitioner or certified family nurse practitioner. See 42 U.S.C. § 1396d~a)
(1994).
[Vol. 11:189
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that prescribed drugs play in modern medical care, prescribed
drugs are not among the enumerated "required" services and,
therefore, historically did not even have to be included in state
plans.4 1 Moreover, the federal regulations piggyback on the dis-
tinction between "required" and "optional" services in circum-
scribing the scope of state discretion in defining the "amount,
duration, and scope ' 42 of these services. 43 As an "optional"
service, prescribed drugs therefore historically could be limited
41 See 42 U.S.C. § 1396a(I0)(A) (1994 & Supp. 1I 1998); see also 42 U.S.C.
§ 1396d(a)(12) (1994). As is evident from the list of "required" care and services, the
term "required" does not necessarily reflect the medical necessity of the care and
services. Prescribed drugs may be "required" in the sense of medical necessity but are
"optional" in the sense of inclusion within a state plan. State plans have recognized
this distinction and all states now include prescribed drugs as a covered service de-
spite the fact that they are optional within a state plan.
42 This term comes from the statutory language governing the quantity of
services that must be provided to Medicaid beneficiaries under an approved state
plan. Section 1902(a) of the Social Security Act provides that, "[a] State plan for
medical assistance must - (10) provide... (B) that the medical assistance made
available to any individual described in subparagraph (A) - (i) shall not be less in
anount, duration, or scope than the medical assistance made available to any other
such individual, and (ii) shall not be less in amount, duration, or scope than the
medical assistance made available to individuals not described in subparagraph (A)."
42 U.S.C. § 1396a(a)(10)(B) (1994 & Supp. H 1998) (emphasis added). These re-
quirements are further defined in the implementing regulations. See 42 C.F.R. §
440.230 (1999).
41 42 C.F.R. § 440.230 (1999) provides as follows:
Sufficiency of amount, duration, and scope.
(a) The plan must specify the amount, duration, and scope of each service
that it provides for -
(1) The categorically needy; and
(2) Each covered group of medically needy.
(b) Each service must be sufficient in amount, duration, and scope to rea-
sonably achieve its purpose.
(c) The Medicaid agency may not arbitrarily deny or reduce the amount,
duration, or scope of a required service under §§ 440.210 and 440.220 to
an otherwise eligible recipient solely because of the diagnosis, type of ill-
ness, or condition.
(d) The agency may place appropriate limits on a service based on such
criteria as medical necessity or on utilization control procedures.
(emphasis added). Subsection (c) only prohibits a state from limiting the
amount, duration or scope of a required service based on the diagnosis, type of
illness, or condition. Since prescribed drugs are not a required service, states
may limit access to prescribed drugs consistent with this provision based on di-
agnosis, type of illness, or condition.
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in ways that would not be permitted for other medically neces-
sary care and services.
44
IV. THE ENACTMENT OF SECTION 1927
Section 1927 was added to the Social Security Act by the
Omnibus Budget Reconciliation Act (OBRA) of 1990.45 As is
common in reconciliation bills, the Act included spending cuts
to bring outlays within limits established by the budget resolu-
tion for that fiscal year.4 6 The House of Representatives de-
scribed the impact of section 1927 in the following language:
44 This issue is discussed at greater length infra in Part IX.A. Some have ar-
gued that Congress should "adequately define the term 'medically necessary' for the
purpose of Medicaid." Carole L. Stewart, Comment, Mandated Medicaid Coverage
of Viagra: Raising the Issues of Questionable Priorities, the Need for a Definition of
Medicaid Necessity, and the Politics of Poverty, 44 LOY. L. REV. 611, 625 (1998).
At a time when Congress is considering so-called "Patient's Rights" bills to prevent
insurance companies from second-guessing physician determinations of medical
necessity, it seems far more appropriate to assign the role of defining "medical neces-
sity" to physicians and other health professionals treating Medicaid patients. Of
course, some of the reasons why commentators have proposed a federal definition
flows from their hostility to such determinations of medical necessity as the perform-
ance of sex reassignment surgery for transsexual patients. See id. at 626 (character-
izing coverage of gender reassignment surgery with public funds as an "absurd" re-
sult). Although the American Psychiatric Association and other professional groups
have determined that gender reassignment surgery is an appropriate treatment for
transsexualism, the lack of sympathy in certain camps for persons suffering from this
disorder has made it an easy target despite the fact that courts have consistently held
that federal law mandates such coverage in appropriate cases. See AMERICAN
PSYCHIATRIC ASS'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS
(DSM-IV) 532-38 (4th ed. 1994) (discussing interest in gender-reassignment surgery
for those with gender identity disorders); see also Rush v. Parham 625 F.2d 1150,
1156-58 (5th Cir. 1980) (invalidating the Georgia exclusion of gender reassignment
surgery from Medicaid reimbursement); Pinneke v. Preisser, 623 F.2d 546 (8th Cir.
1980) (invalidating the Iowa exclusion of sex reassignment surgery from Medicaid
reimbursement); J.D. v. Lackner, 145 Cal. Rptr. 570 (Ct. App. 1978) (requiring cov-
erage of radical sex conversion surgery under Medicaid for treatment of transsexual-
ism); G.B. v. Lackner, 145 Cal. Rptr. 555 (Ct. App. 1978) (rejecting the California
characterization of gender reassignment surgery as cosmetic); Doe v. State Dep't of
Pub. Welfare, 257 N.W.2d 816 (Minn. 1977) (rejecting the Minnesota exclusion of
transsexual surgery from eligibility for medical assistance payments); Denise R. v.
Lavine, 347 N.E.2d 893 (N.Y. 1976) (upholding the denial of female sexual conver-
sion surgery as not medically necessary in this instance).
4- Pub. L. No. 101-508, § 4401, 104 Stat. 1388, 1388-143-159 (1990) (codi-
fied as amended at 42 U.S.C.A. § 1396r-8 (West 1992 & Supp. 2000). Section 4401
provided for reductions in Medicaid spending by altering reimbursement for pre-
scription drugs.
41 See David F. Chavkin & Yvette Hutchinson, A Health Advocate's Guide to
the Federal Budget Process, 15 CLEARINGHOUSE Rsv. 324, 332 (1981) (noting that
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The Budget Resolution also apparently assumes reduc-
tions of $2.38 billion in Medicaid outlays over the pe-
riod FY 1991 through 1995. The Committee bill would
achieve these savings primarily by reforming the pur-
chase of prescription drugs by the States and by requir-
ing the States, where cost-effective, to purchase em-
ployer group health coverage on behalf of Medicaid
beneficiaries.47
Of the $2.38 billion reduction in Medicaid outlays over the
period 1991 to 1995, $2.105 billion was attributed to the
changes in Medicaid reimbursement for prescription drugs.48
Like many provisions in omnibus reconciliation bills, sec-
tion 1927 did not originate in the 1970 Act. Efforts to control
prescription drug prices in the Medicaid program had been in
the works for many years.49 Almost as soon as he was elected to
the Senate, David Pryor of Arkansas began fighting to control
prescription drug prices because of their devastating effect on
the elderly.50 In 1990, Senator Pryor introduced the Medicaid
committees propose specific measures to bring spending within limits). As is also
common, however, it also included spending increases in certain areas. See Omnibus
Budget Reconciliation Act of 1990, Pub. L. No. 101-508, 104 Stat. 1388, 1388-166-
69 (increasing payments to improve child health through mandatory continuation of
benefits throughout pregnancy or first year of life and by adjusting payments for
hospital services furnished to low income children under the age of 6 years); see also
id. at 1388-170-71 (discussing State Medicaid matching payments through voluntary
contributions and State taxes).
47 H.R. REP. No. 101-881, at 65 (emphasis added) (Report of the Committee
on the Budget), reprinted in 1990 U.S.C.C.A.N 2017, 2077. The final version of
section 1927 largely reflected the provisions of the House bill. See H.R. REP. No.
101-964, at 832 (1990), reprinted in 1990 U.S.C.C.A.N. 2526, 2537 (Omnibus
Budget Reconciliation Act of 1990: Conference Report to Accompany H.R. 5835)
(stating, "[t]he conference agreement includes the House bill with amendments to
prohibit the Secretary and the States from reducing drug product reimbursement lev-
els and dispensing fees for pharmacists from the levels in effect August 1, 1990
through March 30, 1995").41 See H.R. RE-P. No. 101-881, at 68.
49 Reconciliation bills often include measures proposed independently as bills
in prior Congresses that could not be passed as separate enactments. By combining
these provisions in an omnibus bill, they can often be passed either as stealth meas-
ures that go largely undetected though the legislative process or as compromise pro-
visions traded by the chairs or ranldng members of authorizing committees.
- As Chair of the Senate Aging Committee, Senator Pryor held numerous
hearings to highlight this issue for legislative action. See Cost of Prescription Drugs,
136 CONG. REc. S5811 (daily ed. May 8, 1990) (statement of Sen. Pryor); see also
Drug Manufacturers: Making Profits on Backs of Poor, 136 CONG. REc. S10,497-04
(daily ed. July 25, 1990) (statement of Sen. Pryor); The High Cost of Prescription
2001]
HEALTH MATRIX
Anti-Discriminatory Drug Price and Patient Benefit Restoration
Act in the 101st Congress.5 1 In introducing this bill, Senator
Pryor accused the drug companies of "holding us captive to
bankrupting the coffers of the State Medicaid drug programs."
52
One of the critical differences between the Pryor bill and the
provision that would be adopted in OBRA 1990 was that the
Pryor bill created a barrier to Medicaid coverage for those drugs
not subject to discounts, rather than an entr6e for drug manu-
facturers with rebate agreements. 53 The only exception under
the initial Pryor bill was the requirement that non-discounted
drugs be made available if a physician obtained prior approval
Drugs, 1989: Hearizgs on S. 9058 Before the Senate Comm. on Aging, 101' Cong.
136 (1989) (statement of Sen. Pryor on the rise in prescription drug prices for the
elderly). In the speeches marking his retirement from Congress, numerous Senators
eulogized this aspect of Pryor's life in Congress. For example, Senator Robert Byrd
paid tribute in the following words:
As the Chairman of the Senate Special Committee on Aging for 6 years,
Senator PRYOR has led the crusade to protect America's elderly and to
oversee Medicare ... His concern for the elderly has led Senator PRYOR to
become an expert on, and a vocal critic of, the prices pharmaceutical com-
panies charge for prescription drugs. And he has matched his criticism with
action. Senator PRYOR was instrumental in requiring drug companies to
charge the same prices to state-federal Medicaid programs for the poor as
they do to other bulk-drug purchasers.
142 CONG. REc. S10,942 (daily ed. Sept. 19, 1996) (statement of Sen. Byrd). Senator
Exon similarly described Senator Pryor as:
A leader in keeping pharmaceutical prices low, Senator Pryor has fought
long and hard to make sure that Americans do not pay for the low prices
pharmaceutical companies charge other countries for their products. Be-
cause of his leadership, the Medicaid program instituted a prescription drug
rebate program so that drugs could be purchased at a more favorable rate.
142 CONG. REC. Sli,265-66 (daily ed. Sept. 25, 1996) (statement of Sen. Exon); see
also 142 CoNG. REc. S11,420-21 (1996) (statement of Sen. Conrad); 142 CoNG. REC.
S 12,300, 12,302 (daily ed. Oct. 3, 1996) (statement of Sen. Lautenberg); 142 CONG.
REc. S 12,281, 12,283 (daily ed. Oct. 3, 1996) (statement of Sen. Kerry).
51 S. 3029, 101' Cong. (1990), 1.-; CONa. Rac. S12,954 (daily ed. Sept. 12,
1990) (introduced) (statement of Sen. Pryor). This bill represented a less ambitious
version of his earlier effort, S. 2605, the Pharmaceutical Access and Prudent Pur-
chasing Act of 1990. See 136 CONG. REc. S5985 (daily ed. May 10, 1990) (statement
of Sen. Pryor who introduced the bill).
52 136 CONG. REc. S12,954 (daily ed. Sept. 12, 1990) (statement of Sen.
Pryor).
53 See Summary of Medicaid Anti-Discriminatory Drug Price and Patient
Benefit Restoration Act of 1990, 136 CONG. REc. S12,962 (1990) (statement of Sen.
Pryor). "The legislation requires that in order to be placed on a Medicaid prescription
drug formulary (the State's covered drug list) - or to be covered by a state Medicaid
program, prescription drug manufacturer must provide the Medicaid program the
same substantial discounts it is giving to other purchasers of its medications." Id.
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from the state Medicaid program. 54 By contrast, the adopted
version is affirmative in its coverage-any drug (subject to the
exclusions in section 1927) manufactured by a drug company
with a rebate agreement must be covered.
55
The Pryor bill was paralleled in the House by the introduc-
tion of H.R. 5589, the Medicaid Prescription Drug Fair Access
and Pricing Act of 1990, by Representatives Ron Wyden and
Jim Cooper.56 As described by Representative Cooper:
[S]ometimes an idea comes along that is so simple, so
powerful, and so compelling that people wonder why it
hadn't been considered years before. Our colleague in
the other body, Senator PRYOR, has come up with such
an idea, and my House colleague RON WYDEN, and I,
are introducing legislation today in the House to imple-
ment that idea.
The idea is simple. When the U.S. Government is a
large purchaser of something, it should be able to nego-
tiate to get either the lowest possible price, or at least as
good a price as other bulk purchasers are getting .... 57
Representative Wyden used even stronger language in ex-
plaining his reasons for introducing H.R. 5589, describing the
legislation as an effort "to stop the rip-off of the Medicaid pro-
" See id.
' In describing his support for this provision of the Omnibus Budget Recon-
ciliation Act of 1990, Senator Orrin Hatch stated as follows:
Although comprising only 40 or so pages of this extremely complex bill,
the drug-discount provision has an important and far-reaching impact...
Of most importance, the Finance Committee plan would provide greater
access for Medicaid patients to FDA-approved drugs than would the House
version. New drugs would be available immediately to Medicaid patients
upon approval by the Food and Drug Administration. These drugs would
not be subject to prior approval and would remain fully available for at
least 12 months before States could consider placing restrictions on them.
Also of utmost importance, the Finance Committee plan, unlike the House
version of the legislation, would prohibit the imposition of formularies,
[restrictive] lists of drugs. Thus, Medicaid patients would have access to
FDA-approved drugs and would not be prohibited from being reimbursed
for necessary medicines.
136 CONG. Rnc. S15,858-59 (daily ed. Oct. 18, 1990) (statement of Sen. Hatch).
56 See 136 CONG. REc. E2813 (daily ed. Sept. 12, 1990) (statement of Rep.
Wyden, Medicaid Deserves Fair Drug Prices).
136 CONG. Rnc. E2826 (daily ed. Sept. 13, 1990) (statement of Rep. Coo-
per on the Medicaid Prescription Drug Fair Access and Pricing Act of 1990).
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gram by pharmaceutical manufacturers." 58 Representative Wy-
den did emphasize that, "[i]n states which use restrictive for-
mularies, beneficiaries will be given new access to a significant
number of prescription drugs for which payment had been pro-
hibited."59 The primary goal of both bills, however, was de-
scribed as an effort "to reduce the approximately $5 billion in
annual State and Federal expenditures for drujs prescribed to
Medicaid beneficiaries on an outpatient basis."
A compromise6 1 version of the Pryor-Wyden-Cooper bills
was included in section 4401 of the Omnibus Budget Recon-
ciliation Act of 1990. 62 This legislative change transformed the
58 Statement of Rep. Wyden, supra note 56, at E2813.
59Id. at E2815.
6o 138 CONG. REc. S16,134 (daily ed. Oct. 1, 1992) (statement of Sen.
Cranston).
61 Drug manufacturers had proposed their own drug discount plans to under-
cut the Pryor-Wyden-Cooper proposal. See Analysis of Drug Manufacturer Medicaid
Drug Discount Proposals and Necessary Elements of Medicaid Drug Price Negotia-
tion Plan (prepared by the Office of Sen. David Pryor), 136 CONG. REc. S12,954,
12,960 (1990).
62 See 136 CONG. REc. S30,515 (1990) (describing prescription drug dis-
counts and reimbursements). These bills would not be the end of efforts to limit gov-
ernment expenditures for prescription drugs. In 1992, Senator Chafee introduced
S2950 to amend title XIX of the Social Security Act "to stop cost shifting by phar-
maceutical companies to health care providers by repealing the use of best price and
increasing the discount used in determining rebates for prescription drugs purchased
under [M]edicaid, to ensure the restoration of prescription drug discounts to various
Federal programs, and for other purposes . . . "' 138 CoNG. REc. S9776 (1992)
(statement of Sen. Chafee). A hearing was held before the Subcommittee on Health
and the Environment of the House Committee on Energy and Commerce regarding
proposals to reform the Medicaid Prescription Drug Rebate Program (HR 2890) and
the Medicaid Prescription Drug Amendments Act of 1992 (HR 5614). See 138 CONG.
REC. D972 (1992) (daily ed. July 31, 1992). Senator Pryor was among the witnesses
who testified. See id. In considering the Veterans Health Care Act of 1992, Senator
Chafee lamented the unintended effect of section 1927 on other purchasers of pre-
scription drugs, especially the Veterans Administration, by increasing costs to these
purchasers. See 138 CONG. REC. S17,743 (daily ed. Oct. 8, 1992) (statement of Sen.
Chafee). In supporting the Veterans Health Care Act of 1992, Senator Rockefeller
described section 1927 in the following language:
A little legislative history is appropriate. In 1990, Senator Pryor, my dear
friend and colleague, offered the Federal Medicaid Program a means to
achieve the discounts that its market share dictates it deserves. As fash-
ioned by Senator Pryor, the Medicaid rebate legislation ensures that the
State and Federal Medicaid partnership receives a minimum discount, now
15 percent. That discount is fair compensation to the Federal Government
for its status as the single, largest purchaser of pharmaceuticals in the
United States. Previously, States had not been successful in obtaining that
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treatment of prescription drugs under the Medicaid program.63
Prescription drugs remained an "optional" service that states
could elect to include in their state Medicaid plans. 64 However,
once a state chose to cover prescription drugs, subject to the
explicit exclusions in section 1927, a state would now be re-
quired to cover all medically necessary prescribed drugs pro-
duced by manufacturers with rebate agreements in effect. 5
It is critical to not lose sight of the quid pro quo embodied
in section 1927 and the significant fiscal savings associated
with passage of this provision.66 In return for the agreements of
discount in their negotiations with manufacturers, despite the clout that
their purchasing power should have commanded.
138 CONG. REc. S17,745 (daily ed. Oct. 8, 1992) (statement of Sen. Rockefeller).
Ironically, it was the savings obtained by the Veteran's Administration through direct
negotiation with the drug companies that helped inspire Senator Pryor's efforts in the
first place. See 136 CoNG. REc. S5813 (daily ed. May 8, 1990) (statement of Sen.
Pryor on the Cost of Prescription Drugs). After the enactment of the reconciliation
bill, Senator Jay Rockefeller analogized Senator Pryor to "David" taking on the "Go-
liath" prescription drug companies with the result that "today we adopted a set of
major legislative reforms that will lower the prices of prescriptions drugs sold to the
Medicaid Program... [by] almost $2 billion." 136 CONG. REc. S17,593 (daily ed.
Oct. 27, 1990) (statement of Sen. Rockefeller).
63 The opportunities for discounts and rebates were limited prior to the enact-
ment of section 1927. See Alan M. Kirschenbaum & Bruce N. Kuhlik, Federal and
State Laws Affecting Discounts, Rebates, and Other Marketing Practices for Drugs
and Devices, 47 FOOD & DRUG L.J. 533, 540-41 (1992) (discussing Medi-
care/Medicaid anti-kickback statute and its exemption involving rebates paid by ven-
dors to group purchasing organizations). The Omnibus Budget Reconciliation Act of
1990 also made other changes affecting the pharmaceutical industry. Andrew S.
Krulwich, The Response to Health Care Reform by the Pharmaceutical Industry, 50
FOOD & DRUG L.J. 1 (1995). Among these changes was the requirement that states
adopt rules requiring pharmacists to counsel patients about prescription drug regi-
mens. See 42 U.S.C.A. § 1396r-8(g) (West Supp. 2000); see also Brenda Jones
Quick, The Cost of the Omnibus Budget Reconciliation Act of 1990, 2 OIo N.U. J.
PHARMACY & L. 145 (1994) (discussing one section of the OBRA of 1990 that puts
the duty on each state to pass laws making pharmacists take on legal responsibilities,
including counseling patients and obtaining patients' medical histories).
Pursuant to section 1902(a)(10)(A) of the Social Security Act (42 U.S.C.
§1396a(a)(10)(A) (1994)) and section 1905(a)(12) (42 U.S.C. §1396d(a)(12) (1994)),
"prescribed drugs" remain an optional service that may be provided to the categori-
cally and medically needy.
s As described in the House Report, "the Committee bill would require States
that elect to offer prescription drugs to cover all of the products of any manufacturer
that agrees to provide price rebates." H.R. REP. No. 101-881, at 97 (1990), reprinted
in 1990 U.S.C.C.A.N. 2017,2109.
0 PhRMA, the Pharmaceutical Research and Manufacturers of America, was
and is a potent political force. See David S. Hilzenrath, Drug Firms Rename Lobby-
ing Group: Industry Hopes to Make Itself More Sympathetic During Care Debate,
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manufacturers to limit their charges to state Medicaid programs,
states are limited in their discretion in deciding whether to pro-
vide reimbursement for specified drugs in their Medicaid
plans. 67 States would benefit from reduced costs for drugs;
manufacturers would benefit from an unrestricted formulary.63
WASH. PosT, May 3, 1994, at D3 (noting the 100 firms the lobby represents); see also
Brian L. Walser, Shared Technical Decisionmaldng and the Disaggregation of Sor-
ereignty: International Regulatory Policy, Expert Communities, and the Multina-
tional Pharmaceutical hIdustry, 72 Tuo. L. REv. 1597, 1648 (1998) (remarking upon
the "uncommon degree of internal organization among multinational pharmaceutical
companies"); Medicaid Anti-Discriminatory Drug Price and Patient Benefit Restora-
tion Act of 1990, 136 CONG. REc. S12,954, 12,954-01 (1990) (statement of Sen.
Pryor).
However, this power has been achieved at significant costs as the drug com-
panies learned when they "were told in a confidential report... that in the public
mind they ranked as low as the tobacco industry... Neil A. Lewis with Robert
Pear, U.S. Drug Industry Fights Reputation for Price Gouging, N.Y. TIMES, Mar. 7,
1994, at B6. The name of the trade association was changed in order to make it more
sympathetic to the public by "emphasiz[ing] drug companies' investment in the de-
velopment of medicines .... Hilzenrath, supra. According to Public Citizen's Con-
gress Watch, the drug makers spent more on lobbying in 1999 than any other indus-
try. See Nancy McVicar, Drug Lobbying Irks Consumer Group: $236 Million Spent
to Combat Prescription Plan, SuN-SENTNEL (Ft. Lauderdale), July 9,2000, at I IA.
In order to achieve the savings associated with section 1927, savings that
would come at the expense of pharmaceutical company profits, there needed to be
associated benefits for the drug companies - an opened market for all drugs subject to
rebate agreements. The existence of that quidpro quo seems to have been ignored by
those commentators who have focused on the Medicaid expenses of the quo without
acknowledging the Medicaid savings from the quid.
61 As noted by the House Budget Committee:
Under current law, States may, at their option, offer coverage for pre-
scribed drugs .... States may limit the number or [sic, of) prescription
drugs which they cover through a formulatory [sic, formulary].... Tihe
Committee bill would require States that elect to offer prescription drugs to
cover all of the products of any manufacturer that agrees to provide price
rebates.
H.R. REP. No. 101-881, at 95-97 (1990), reprinted in 1990 U.S.C.C.A.N. 2107,
2107-2110.
6 Unfortunately, casual readers of the Medicaid statute often miss this dis-
tinction. Prescription drugs are "optional" services only in the historical sense that
they were not among the original services that states were "required" to provide to
the categorically needy. However, since the enactment of section 1927, coverage of
prescription drugs subject to rebate agreements has been effectively "required" in
state Medicaid plans. One commentator attempted to capture this distinction in the
following language: "The federal statute which sets forth the requirements for Medi-
caid payment of prescription drugs provides that no drug will be covered by any state
Medicaid program unless the manufacturer of the drug has entered into an effective
'rebate agreement' with the Secretary of Health and Human Services." Stewart, supra
note 44, at 616. In fact, a state could choose to cover a prescription drug even if the
manufacturer did not enter into a rebate agreement, but would not be required to do
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Reading these provisions together with the unmodified
prior statutory and regulatory requirements 69 governing pre-
scribed drugs under Medicaid, state Medicaid programs must
cover those drugs from manufacturers with rebate agreements
so long as the drugs are not otherwise excluded by federal law.
However, these drugs may be subjected to limitations on the
amount, duration, and scope of coverage,70 may be subjected to
prior authorization in some cases,71 and may be subjected to
utilization review.
72
V. THE CLINTON ADMINISTRATION POSITION
On July 2, 1998, the Health Care Financing Administra-
tion7I issued a letter to the states addressing the issue of "Medi-
caid Coverage of Viagra." 74 As noted in this letter, "[tihe issue
so. Rather, it would be far more accurate to describe the status of prescription drugs
under Medicaid as follows: The federal statute which sets forth the requirements for
Medicaid payment of prescription drugs provides that if a manufacturer of a drug
has entered into an effective rebate agreement with the Secretary of Health and Hu-
man Services that drug must be covered by every, State unless coverage of the drug is
othenvise excluded. This phrasing undercuts any attempt to argue that, pursuant to
the Chevron Doctrine (announced by the United States in Chevron U.S.A., Inc. v.
Natural Resources Defense Council, Inc., 467 U.S. 837 (1984)), the Health Care
Financing Administration (HCFA) has exceeded its authority. See Stewart, supra
note 44, at 619-23 (discussing application of the Chevron Doctrine to HCFA regula-
tory initiatives in this area).
69 Final regulations have not yet been issued to implement section 1927. Pro-
posed regulations were issued at 60 Fed. Reg. 48,442 (1995) (to be codified at 40
C.F.R. pts. 441 & 447) (proposed Sept. 19, 1995).70 See 42 C.F.R. § 440.230(c) (1999).
71 When an item of care or services is subject to prior authorization, a pro-
vider (and in some cases a beneficiary) must obtain approval from a review entity
within or outside of the state Medicaid agency before reimbursement will be made
for the care and services under the state plan.
72 When an item of care of services is subject to utilization review, a reviewer
or review entity within or outside of the state agency administering the medical as-
sistance program reviews the delivery of care or services to determine the appropri-
ateness of such delivery. Such review is ordinarily conducted after the care or serv-
ices have been delivered but may occur before payment is made.
73 See Reorganization Order, Dep't of Health, Educ. & Welfare, 42 Fed. Reg.
13,262 (1977).
74 See Health Care Financing Admin., Drug Policy: Medicaid Coverage of
Viagra (last modified July 24, 1998) <http:llwww.hcfa.gov/medicaidldrpolicy.htm>.
This directive supplemented the State Medicaid Directors' Drug Rebate Program
Release No. 81, issued on July 2, 1998. See also HCFA Tells States to Pay for
Viagra; Pledges to Conduct Rigorous Monitoring, Health L. Rep. (BNA) at 1096
(July 9, 1998). As indicated by the survey results in Appendix A, rigorous monitor-
ing never occurred.
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of whether State Medicaid programs must cover Viagra is gov-
erned by the Omnibus Budget Reconciliation Act of 1990,
which established the drug rebate program at section 1927 of
the Social Security Act (the Act).";75 As HCFA explained, "a
State that chooses to include outpatient drugs within its Medi-
caid program must cover, for their medically accepted indica-
tions, all FDA approved prescription drugs of manufacturers
that have entered into drug rebate agreements." 76 HCFA then
noted that use of Viagra to treat erectile dysfunction in men is
not subject to any allowable exclusion or restriction, and that
the Secretary had not determined that the drug was subject to
clinical abuse or inappropriate use.7 7 Therefore, HCFA con-
cluded that, "the law [section 1927] requires that a State's
Medicaid program cover Viagra when medical necessity dic-
tates such coverage for the drug's medically accepted indica-
tion."7
8
VI. THE STATE RESPONSE
The reaction to the Clinton Administration pronounce-
79 80ment was immediate and critical. On July 2, 1998, the Na-tional Governors' Association (NGA), 81 the American Public
7 5 Health Care Financing Admin., supra note 74.
76 id.
77 See id.
78 Id.
79 Although some commentators have referred to the HCFA letter as a "direc-
five" that term invests the letter with more official status than it deserves or than it
purported to possess. See Stewart, supra note 44, at 612. As a form of "interpretive
rule," the letter merely explained what was already a requirement by operation of
federal statute - section 1927 of the Social Security Act. It could not impose new
substantive requirements. See American Hosp. Ass'n v. Bowen, 834 F.2d 1037, 1045
(D.C. Cir. 1987).
o See Robert Pear, New York and Wisconsin Will Defy Federal Directive to
Provide Viagra Through Medicaid, N.Y. TIMES, July 3, 1998, at A12.
81 The National Governors' Association describes itself as:
Tihe only bipartisan national of, by, and for the nations' Governors. Its
members are the Governors of the fifty states, the commonwealths of the
Northern Mariana Islands and Puerto Rico, and the territories of American
Samoa, Guam, and the Virgin Islands .... Through NGA, the Governors
identify priority issues and deal collectively with issues of public policy
and governance at both the national and state levels. The association's mis-
sion is to provide a forum for Governors to exchange views and experi-
ences among themselves; assistance in solving state focused problems; in-
formation on state innovations and practices; and a bipartisan forum for
Governors to establish, influence, and implement policy on national issues.
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Welfare Association (APWA),82 and the National Association
of State Medicaid Directors (NASMD) 83 publicly opposed the
decision mandating Medicaid coverage of Viagra.
4
National Governors' Ass'n, NGA Online: The Organization (visited July 5, 2000)
<http://www.nga.orglsubtocnga.htm>.
2 The American Public Welfare Association is now the American Public
Human Services Association (APHSA). The Association describes itself as:
A nonprofit, bipartisan organization of individuals and agencies concerned
with human services. Our members include all state and many territorial
human service agencies, more than 1,200 local agencies, and several thou-
sand individuals who work in or otherwise have an interest in human serv-
ice programs. APHSA educates members of Congress, the media, and the
broader public on what is happening in the states around welfare, child
welfare, health care reform, and other issues involving families and the
elderly. The association's mission is to develop, promote, and implement
public human service policies that improve the health and well-being of
families, children, and adults. APHSA is also an umbrella for several com-
ponent groups. First among these are the National Council of State Hu-
man Service Administrators and the National Council of Local Human
Service Administrators. APHSA's affiliate groups include the American
Association of Food Stamp Directors, American Association of Public
Welfare Attorneys, American Public Human Service Association-Infor-
mation Systems Management, Association of Administrators of the Inter-
state Compact on the Placement of Children, National Association for Pro-
gram Information and Performance Measurement, National Association of
Public Child Welfare Administrators, National Association of State TANF
Administrators (NASTA), National Association of State Medicaid Direc-
tors, National Association of State Child Care Administrators (NASCCA),
and the National Staff Development and Training Association.
American Pub. Hum. Serv. Ass'n, About APHSA (visited Oct. 11, 2000)
<http:lwww.aphsa.orglaboutlabout.htm>.
83 The National Association of State Medicaid Directors (NASMD)describes
itself as:
[A] bipartisan, professional, nonprofit organization of representatives of
state Medicaid agencies (including the District of Columbia and the territo-
ries). Since 1979, NASMD has been affiliated with the American Public Hu-
man Services Association (APHSA). The primary purposes of NASMD are to
serve as a focal point of communication between the states and the federal
government and to provide an information network among the states on is-
sues pertinent to the Medicaid program.
National Ass'n of State Medicaid Dirs., About NASMD (visited Oct. 10, 2000)
<http://medicaid.aphsa.orglNASMD.htm>.
4 See National Governors' Ass'n, Press Release, Viagra Decision Represents
Unfinded Mandate: "NGA Opposes HastV Decision That Increases State Costs and
Limits Fleibilit) (July 2, 1998) <http://www.nga.org/Releases/PR-2July
1998Viagra.htm>; Letter from Linda Wolf, Acting Executive Director, American
Pub. Welfare Ass'n, to the Hon. Donna Shalala, Secretary, U.S. Dep't of Health &
Hum. Serv., APWA and NASMD Denounce Decision to Mandate Medicaid Coverage
of Viagra. July 2, 1998 (visited Oct. 14, 2000)
<http://www.apwa.orglhotnews/viagra.htm>.
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In its Press Release, the National Governors' Association
"expressed strong opposition to an unfunded mandate." 85 Of
course, independent of the legality or illegality of the action by
the Clinton Administration, the mandate is hardly "unfunded."
As with other medical assistance services provided pursuant to
an approved state plan, the federal government funds between
50 and 83 percent of the costs of care and services.86 To be
more accurate then, the requirement is better described as a
mostly-funded mandate.
On the same day that the National Governors' Association
issued its press release, the American Public Welfare Associa-
tion and the National Association of State Medicaid Directors
sent a letter to Secretary Shalala expressing concerns about the
"recent decision mandating Medicaid coverage of the drug
Viagra.' ' sT This APWA/NASMD letter described the potential
for abuse of the drug and the increasing reports of contraindica-
tions. 8 Based on these factors, the letter expressed disappoint-
ment that additional time had not been allowed to gain experi-
8 National Governors' Ass'n, supra note 84. The issue of "unfunded" man-
dates remains a major focus for the National Governors' Association. See Federal-
ism: Hearings on S. 1214 before the Senate Comm. on Governmental Affairs, I0 6 h
Cong. 153-62 (1999) (prepared statement of Governor Michael 0. Leavitt, Utah,
Vice Chairman, National Governors' Ass'n) (testifying about the problems of federal
preemption of state laws and unfunded mandates); see also Donald F. Kettl, 10th
Amendment Turf War, GOVmRNI.G, Oct. 1998, at 13 (outlining the 10,h Amendment
state/local and federal government's powers debate in light of the decision of the
Department of Health and Human Services' ruling that States must make Viagra
available to those receiving Medicaid).
86 See 42 U.S.C. § 1396b(a)(1) (1994) (describing the computation of the
amount of payment to States that have a plan approved under this subchapter as ref-
erenced in 42 U.S.C. § 1396d(b) (1994)).
87 Letter from Linda Wolf, supra note 84.
88 Among the concerns associated with the use of Viagra are the cardiac risks
associated with sexual activity. As described by Pfizer, "ft]here is a potential for
cardiac risk of sexual activity in patients with preexisting cardiovascular disease.
Therefore, treatments of erectile dysfunction, including Viagra, should not be gener-
ally used in men for whom sexual activity is inadvisable because of their underlying
cardiovascular status." See Viagra.com, supra note 32. These risks were emphasized
in the follow-up communication to health professionals reflecting safety information
obtained through post-marketing experience. In that communication, Pfizer warned
that, "[s]erious cardiovascular events, including myocardial infarction, sudden car-
diac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic
attack, and hypertension, have been reported post-marketing in temporal association
with the use of VIAGRA. Most, but not all of these patients had preexisting cardio-
vascular risk factors." Id.
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ence with the drug before mandating state coverage. s9 While
this language suggested a more reasoned and less hysterical re-
sponse to the federal action than the NGA communication, the
letter went on to again criticize the federal requirement as "an
unfunded mandate that is conservatively estimated to cost a
minimum of $100 million per year."90 Several states announced
that they would not comply with the HCFA directive.
91
See Letter from Linda Wolf, supra note 84.
Id.; see also National Governors' Ass'n, supra note 84. In another setting,
Elaine Ryan, government affairs director for the American Public Welfare Associa-
tion, was quoted as estimating costs as high as $200 million attributable to coverage
of Viagra. See Amy Goldstein, U.S. Tells States to Cover Viagra Prescriptions Under
Medicaid, WASH. PosT, July 3, 1998, at A21.
Total costs for all prescribed drugs and other non-durable medical supplies
under the Medicaid program amounted to only $15.5 billion in calendar year 1998.
See Health Care Financing Admin., National Health Care Expenditures, 1998 Na-
tional Health Expenditures: Expenditures for Health Serices and Supplies Under
Public Programs, by Type of E.xpenditure and Program, Table 10 (visited Oct. 12,
2000) <http:llwww.hcfa.gov/statslnhe%2DoactltablesltlO.htm>. Moreover, the issue
of inflated cost estimates has not been limited to states opposing federally-mandated
coverage of Viagra. As described by Dr. Mike Magee, Senior Medical Advisor for
Pfizer
We first got into the public debate on this in California some six or eight
weeks ago. Kaiser had made a very public statement that they were not
going to cover Viagra because the cost was so extraordinary; that it would
lead to people dropping off of insurance rolls and would increase the num-
ber of uninsured. As a result, the Commissioner of the Department of Cor-
porations in California called public hearings in San Francisco and Los
Angeles. At the public hearings we decided to play a role.
At those public hearings Kaiser stated that this drug would cost their
plan $150 million. The Commissioner asked our reaction to that. Our reac-
tion was that that would be extraordinary consumption indeed, and that
Kaiser represents a point or two market share nationwide, and $150 million
is about 25 percent of the total revenue that we will yield for the year in the
U.S. from Viagra. It would have been extraordinary consumption on the
part of Kaiser men to consume that much Viagra. That was quite clear.
The Commissioner followed up and asked Kaiser what their script expe-
rience had been thus far in the first five months. Kaiser said they did not
have that data available. The physician president of Blue Shield then stood
up in front of the Commissioner and said that Viagra would cost $36 bil-
lion. The Commissioner said that's an extraordinarily high number. Where
did you get that number? He said, it's quite easy. There are 30 million men
in America who have an erectile dysfunction. The product costs $10 per
pill. They'll use 10 pills per month, and there are 12 months in a year. So,
it's going to cost $36 billion, and so you should not use this because it's
going to break the bank.
They then asked us what our reaction to that was. My reaction was, it's
true there are 30 million men in the United States who have an erectile dys-
function, but our script experience then at five months allowed us to abso-
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Neither the NGA letter nor the APWA/NASMD letters di-
rectly challenged the HCFA interpretation of federal law as be-
ing inconsistent with the Social Security Act. Instead, these is-
suances focused on the financial impact on states and on the
adverse effect on federal-state relations.
92
Both of these communications, therefore, miss the central
point. If the Administration reading of section 1927 of the So-
cial Security Act was correct, then the Administration would
lutely predict that only 15 percent of the men would come forward for
Viagra .... In addition to that, we knew that approximately 15 percent of
those men who actually did come forward would never get Viagra because
they would be on nitroglycerin. It would be contraindicated .... Another
15 percent would have to be knocked off. On top of that... [i]t would only
work in approximately 70 percent of the men. So, by the time you started
subtracting off, we knew that the rates that were being cited, whether it
would be by Medicaid with a hundred million dollar figure or whether it
would be by Kaiser or Blue Cross and Blue Shield, were at least tenfold
escalated.
Transcript of Pennsylvania Hearing, supra note 36, at 14-16. In addition, it is impor-
tant to recognize that there are offsetting cost reductions associated with covering
Viagra. As noted by Dr. Magee:
[E]rectile dysfunction is a marker disease. We know from a variety of dif-
ferent aging studies that if you bring in one million men age 40 to 70 to see
the doctor, that in that one million men you will uncover 30,000 cases of
untreated diabetes. You'll uncover 50,000 cases of untreated heart disease.
You'll uncover 140,000 cases of untreated hypertension.... We know that
if men will come in with this problem, in the course of a simple history and
physical examination, EKG, blood glucose, diseases will be uncovered
early in their stage when they are very cost-effectively treated compared to
late ... if you do a cost-benefit analysis on this, you must include the cost
savings that would come by having brought these men into the system who
otherwise would not come in.
Id. at 17-18. These estimates also ignore the impact on men's lives that may result in
such benefits as increased work productivity that may further offset cost estimates.
The Medicaid experience from the first quarter attributable to coverage of Viagra
showed expenditures under one million dollars. See id. at 22. The projections are that
the expenditures after full implementation will "come in well under $10 million;
probably closer to $5 million." Id.; see also Medicaid Viagra Cost Estimates Over-
stated at Least 10-Fold- Pfizer, PINK SHEET, Nov. 2, 1998, at 9.
91 See Several States Oppose HCFA Order to Pay for Anti-Impotence Drug
Viagra, 7 HEALTH L. REP. (BNA) No. 29, at 1138 (July 16, 1998). Leigh Page, States
Revolt at Covering Viagra Under Medicaid, AM. MED. NEws, July 20, 1998, at I.
92 The National Governors' Association also argued that Viagra was still an
unproven drug with potentially serious side effects. See E-mail from Matt Salo, Sen-
ior Health Program Analyst, National Governors' Ass'n, to Leidys Dominguez, Re-
search Assistant (June 10, 1999) (copy on file with author). Some states also ex-
pressed concern that Viagra was no more "medically necessary" than drugs that could
be excluded under section 1927. See id. Of course, that argument does not change the
express language of the exclusions in section 1927.
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have had no discretion to permit states to exclude Viagra from
coverage under approved Medicaid plans. Likewise, if the Ad-
ministration reading of section 1927 was incorrect, then the
Administration would have had no authority to require states to
cover Viagra under approved Medicaid plans.
VII. THE ATTEMPT AT A CONGRESSIONAL
END-RUN
Critics of the Administration interpretation immediately
undertook an effort to preempt the HCFA announcement
through recourse to Congress. Through a change in federal law,
opponents of Medicaid coverage of Viagra hoped to eliminate
any requirement imposed by section 1927. 93
H.R. 4274 was the appropriations bill in the 10 5th Congress
for the Departments of Labor, Health and Human Services, and
Education, and related agencies for the fiscal year ending Sep-
tember 30, 1999. On July 20, 1998, less than three weeks after
the HCFA policy issuance, the House Appropriations Commit-
tee reported an appropriations bill covering the Department of
Health and Human Services.94 Section 218(a) of that bill con-
tained the following language:
LIMITATION ON USE OF FUNDS FOR VIAGRA. -
Except for postsurgical treatment, none of the funds ap-
propriated in this Act shall be expended by the Health
Care Financing Administration to reimburse States for
Viagra under section 1927 of the Social Security Act.
95
Section 218(a) thereby would have excluded from Medicaid
reimbursement any costs attributable to the provision of Viagra
to Medicaid beneficiaries. Section 219 contained the following
additional language:
No funds made available in this Act may be used to take
any administrative action against States that do not
cover Viagra or any other drug or device under section
'." In fact, it was feared that the proposed change in federal law would not
only eliminate the requirement, but would actually require states to halt Medicaid
funding for the treatment of erectile dysfunction. See Bob Gatty, States May Be
Forced to Half Funding for Impotence Tx, UROLOGY TIMEs (Sept. 1, 1998), at 2.
"
4 See H.R. REP. No. 105-635 (1998) (Appropriations Bill for Dep't of Labor,
Health & Hum. Serv., and Educ., and Related Agencies-to Accompany H.R. 4274).
"-" H.R. 4274, 105 "' Cong. § 218(a) (1998).
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1927 of the Social Security Act for the treatment of
erectile dysfunction. 96
Section 219 thereby would have insulated any State excluding
Medicaid coverage for Viagra from any compliance proceeding
on the grounds that the state plan did not comply with govern-
ing federal law.
9 7
Sections 218(a) and 219 of H.R. 4274 did not become law,
however, as the Conference Committee rejected the House pro-
vision.98 On November 30, 1998, with its interpretation of fed-
9 6 H.R. 4274, 10 5 th Cong. § 219 (1998).97 Pursuant to section 1904 of the Social Security Act, state plans are subject
to a compliance proceeding process as follows:
Operation of State plans.
If the Secretary, after reasonable notice and opportunity for hearing to the
State agency administering or supervising the administration of the State
plan approved under this subchapter, finds-
(1) that the plan has been so changed that it no longer complies with the
provisions of section 1396a of this title; or
(2) that in the administration of the plan there is a failure to comply sub-
stantially with any such provision;
the Secretary shall notify such State agency that further payments will not
be made to the State (or, in his discretion, that payments will be limited to
categories under or parts of the State plan not affected by such failure), un-
til the Secretary is satisfied that there will no longer be any such failure to
comply. Until he is so satisfied he shall make no further payments to such
State (or shall limit payments to categories under or parts of the State plan
not affected by such failure).
42 U.S.C. § 1396(c) (1994). The range of options available to the Health Care Fi-
nancing Administration to bring states into compliance with federal law also includes
other mechanisms for withholding federal funds. See Eleanor D. Kinney, Ride and
Policy Making for the Medicaid Program: A Challenge to Federalism, 51 OHIO ST.
L.J. 855, 863-64 (1990) (detailing options such as compliance actions, disallowance
actions, and the quality control system).
Some legislators did not wait for the legislative process to be completed.
Representative David McIntosh, CI..irman of the Regulatory Subcommittee of the
House Government Reform and Oversig t Committee, pronounced, in a letter to all
50 governors, that the HHS directive "has no legal force or effect and should not be
regarded as binding on the states." States Told to Ignore Viagra Directive, SUNDAY
ADVOCATE (Baton Rouge, La.), Aug. 9, 1998, at 12-A (quoting Rep. David McIntosh,
R-Ind.). Of course, the HHS directive was never intended to have the legal force or
effect of law. See id. Rather, all it purported to do was remind states of the existing
requirements of federal law - section 1927 of the Social Security Act.
98 The Conference Report provided as follows:
Medicaid Funding for Viagra.
The conference agreement does not include sections 218 and 219 of the
House bill. The Senate bill contained no similar provisions. There are con-
cerns about clinical and financial abuse of these drugs that could endanger
the health of patients and undermine the public support for the Medicaid
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eral law undisturbed by Congress, HCFA again reminded the
states that they must cover Viagra.
99
Meanwhile, States quickly divided into three camps. Most
immediately added coverage of Viagra to their Medicaid pro-
grams.' °° A few "weighed" the mandate and their restonse to
the HCFA directive before adding coverage of Viagra. Others
chose to exclude Viagra from coverage. T0 We must therefore
program that often cannot adequately provide basic health care for all
needy individuals. Therefore, HCFA is encouraged to establish a rigorous
system to review utilization of these drugs by working with States, clini-
cians, consumer advocates, and others to assure consistent collection of
data necessary to make the exclusion determination under section
1927(d)(3) if the drug is subject to clinical abuse or inappropriate use.
H.R. REP. No. 105-825, at 1294 (1998) (Report entitled Making Omnibus Consoli-
dated and Emergency Supplemental Appropriations for Fiscal Year 1999: Contfer-
ence Report to Accompany H.R. 4328).
" See Letter from Sally K. Richardson, Director, Center for Medicaid & State
Operations, Health Care Financing Admin. (HCFA), to State Medicaid Directors
(Nov. 30, 1998) (reprinted at <http:ll/wvw.hcfa.gov/medicaidlsmdl1308.htm> (on
file with the author).
10o Section 1927 requires coverage of all approved drugs manufactured by
drug companies that have rebate agreements in effect. There is no waiting period in
the statute. Despite this fact, Medicaid coverage of Viagra was not automatic in many
states. For example, New York argued that, "[i]t is the State's right to review specific
drugs for any time necessary to determine whether or not there are state issues per-
taining to the coverage of a drug:' E-mail from Mark Butt, Director of Pharmacy
Policy & Operations, Bureau of Program Guidance, Office of Medicaid Management,
N.Y. State Dep't of Health, to Leidys Dominguez, Research Assistant (June 23,
1999) (on file with author).
11l See generally Medicaid-Prescription Drugs: Several States Oppose HCFA
Order to Pay for Anti-Impotence Drug Viagra, 7 Health Law Rep. (BNA) 1138,
1138-39 (July 16, 1998) (describing how states have struggled with the issue of in-
cluding Viagra in their Medicaid program). South Carolina and Michigan fell into
this camp. In Pennsylvania, a hearing, "Access to Pharmaceutical Services in the
Medical Assistance Program," was held on October 8, 1998 before the Health and
Human Services Committee of the Pennsylvania House of Representatives. See Tran-
script of Pennsylvania Hearing, supra note 36 (describing the apparent need for
Pennsylvania to convene a special committee among the House to "weigh" these
issues).
102 New York and Oregon fell into this camp. Matt Salo, Senior Health Policy
Analyst for the National Governors' Ass'n, stated that these states that are not cov-
ering the drug at all "are not doing so in a blatant attempt to flaunt HCFA authority,"
but instead because they are "truly concerned about the social and fiscal implications
of covering the drug." E-mail from Matt Salo, supra note 92.
Oregon is an especially complicated state to analyze because it operates its
Medicaid program pursuant to a broad waiver of many federal requirements. See 4
Medicare & Medicaid Guide (CCH) 15,630 (introducing Oregon's Medicaid pro-
gram as a § 1115 demonstration project waiver known as the Oregon Health Plan).
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resolve the question of whether the Administration interpreta-
tion of federal law is correct since Medicaid plan compliance is
at stake in the states deviating from the HCFA directive.
03
VIII. THE IRONY OF THE DISPUTE
It is ironic that the first major dispute about the application
of section 1927 has arisen in the context of a medication tar-
This program expands eligibility to poverty level individuals (133% of
poverty level for pregnant women, infants and children under age six).
Services are delivered by fully and partially capitated plans and primary
care case management programs. A public prioitization process is used to
establish the service package provided under the Oregon Health Plan. Im-
plementation of this waiver was February 1, 1994 ....
Id.; see also John Kitzhaber & Mark Gibson, The Crisis in Health Care-The Oregon
Health Plan as a Strategy for Change, 3 STAN. L. & PoL\" REv. 64 (1991) (discuss-
ing whether the Oregon plan is a reasonable step in moving from a failing system to
one that works). See generally James V. Garvey, Note, Health Care Rationing and
the Americans with Disabilities Act of 1990: What Protection Should the Disabled Be
Afforded, 68 NoTRE DAME L. REv. 581, 586 (1993) (listing the primary principles
behind the Oregon plan); Greg P. Roggin, The "Oregon Plan" and the ADA: Toward
Reconciliation, 45 WASH. U. J. URB. & CONTEMP. L. 219 (1994) (describing the his-
tory and current status of the Oregon Basic Health Services Act).
The State currently offers treatment for 574 conditions out of a list of 743
compiled by Oregon Health Plan officials. See Oz Hopkins Koglin, State Health
Officials Urged to Restore Viagra Coverage, T-E OREGONIAN, Aug. 27, 1998, at D9.
Impotence caused by organic problems ranks number 542 on the list of 574 funded
items and is therefore covered for treatment with Viagra. By contrast, impotence
caused by inorganic sources, such as mental disorders, ranks number 578, and treat-
ment is therefore not covered. See Insurers Develop Strict Rules on Coverage for
Impotence Pills, THE OREGONIAN, Apr. 29, 1998, at Al, A16; Viagra Coverage:
Oregon Says 'Yes,' But Not Alabama, AM. HEALTH LINE, May 8, 1998. By the fall of
1998, that situation had changed and Oregon terminated its coverage of Viagra. This
was accomplished by reclassifying all treatment with Viagra from organic disorders
on line 544 to sexual dysfunction of psychological origin on line 578. See Hopkins
Koglin, supra.
Effective June 1, 1999, the New York Medicaid agency announced that it
would cover Viagra under its State Medicaid program. See Letter from Gregor N.
Macmillan, Director of Provider Relations, Office of Medicaid Management, De-
partment of Health, State of New York to New York pharmacists (June 3, 1999) (on
file with author); see also New York Dep't of Health, Attention Medical Prescribers
and Pharmacy Providers, DOH MEDICAID UPDATE, June 1999 (visited Oct. 12,2000)
<http:llwww.health.state.ny.uslnysdohlmancare/ommlO699med.htm>. New York
decided to add Medicaid coverage of Viagra after legislative efforts to expand the
authority of the Secretary of Health and Human Services to exclude drugs like Viagra
from Medicaid coverage or to expand the authority of the states to exclude certain
drugs from coverage. See E-mail from Mark Butt, supra note 100.13 See 42 U.S.C. § 1396(c) (1994) (explaining State compliance plan).
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geted at men, usually of advanced years. 104 Because of the eli-
gibility requirements of the Medicaid program, the vast majority
of Medicaid beneficiaries are children and female caretaker
relatives. 0 5 Although elderly and disabled beneficiaries do
utilize the majority of services under State Medicaid programs,
primarily for coverage of long-term care, it is not clear that
people in nursing homes and chronic care hospitals really are
the target population for Viagra.
It is also ironic that it was the Clinton Administration that
chose to create a confrontation with the states over this issue.
As Governor of Arkansas, Bill Clinton was one of the three
drafters of a resolution for the National Governors Association
opposing the enactment of any new Medicaid mandates by
Congress. 0 6 That resolution was supported by nearly every
governor. 0 7 The Congressional amendments, adamantly op-
1,4 Research on the use of Viagra in women has been less promising. See
Steven A. Kaplan et al., Safet, and Efficacy of Sildenafil in Postmenopausal Women
with Sexual Dysfunction, 53 UROLOGY 481 (1999) (concluding that, while sildenafil
was well tolerated in postmenopausal women with sexual dysfunction, overall sexual
function did not improve significantly).
l,)5 HCFA has emphasized that since "only about 10 percent of Medicaid
beneficiaries are adult males," the number of patients who could be diagnosed with
erectile dysfunction is rather small. Prescription Drugs: HCFA Tells States to Pay for
Viagra; Pledges to Conduct Rigorous Monitoring, 7 Health Law Rep. (BNA) 1096,
1097 (July 9, 1998). There appears to be a small, but potentially important, role that
Viagra (sildenafil) can play for certain women. See H. George Nurnberg, et al., Silde-
nafil .for Women Patients with Antidepressant-Induced Sexual Dysfunction, 50
PSYCHIATRIC SERVICES 1076 (1999).
1('6 The other drafters were then-Governor Richard Celeste of Ohio, then
Chairman of NGA's Committee on Human Resources, and then-Governor Garrey
Carruthers of New Mexico. See Julie Rovner, Governors' Medicaid Protests Likely
to Be Swept Aside, 47 CONG. Q. WKLaY. REP. 2121, 2122 (1989). Clinton's role be-
came the focus of an effort by the Children's Defense Fund, an organization that was
then chaired by Hillary Clinton, to expose Clinton's perceived hypocrisy in opposing
legislation that was an outgrowth of efforts by the Southern Regional Project on In-
fant Mortality, a task force led by former Governor Richard W. Riley of South Caro-
lina, and that was consistent with positions espoused by Clinton in many public
speeches. See id. at 2121; see also Maria Henson, Children's Fund Criticizes Clinton
on Medicaid Issue: Governors Association Letter Assailed, ARK. GAzEsri, Aug. 19,
1989, at lOB.
107 The only governor who refused to sign the resolution was Mario M. Cu-
omo of New York. See Letter from National Governors' Ass'n to Members of Con-
gress (Aug. 1, 1989) (on file with author). As explained by Brad C. Johnson, head of
New York State's Washington D.C. office:
We are not opposed to expansion of Medicaid to poor pregnant women, in-
fants and children and that's why we did not sign the letter... Congress is
2001]
HEALTH MATRIX
posed by the governors, were ultimately enacted to expand
Medicaid eligibility and services for low-income children and
pregnant women. 
0
The Clinton Administration has also taken the lead in
granting waivers of provisions of the Medicaid statute, '1 9 in-
on the right track, and as long as they're willing to pay part of the freight,
we're willing to go along.
Rovner, supra note 106, at 2122. Then-Governor Buddy Roemer of Louisiana also
failed to sign the resolution. However, he spoke in favor of the resolution at the NGA
meeting, but could not be located before the letter was sent. Id.
108 The bipartisan proposal was initially proposed by President Bush in his
Fiscal Year 1990 budget. See Rovner, supra note 106, at 2121. That proposal would
have required "states to cover infants and pregnant women in families with incomes
up to 130 percent of the poverty level." Id. The House Energy and Commerce Com-
mittee and Senate Finance Committee bills would have required "states to extend
Medicaid coverage to pregnant women and to infants up to age I in families with
incomes below 185 percent of the federal poverty [line]" Id As finally enacted, the
legislation achieved several goals. First, it mandated eligibility for low-income preg-
nant women and infants with family incomes up to 133 percent of the federal poverty
line. See 42 U.S.C.A § 1396a(l) (West Supp. 2000); Omnibus Budget Reconciliation
Act of 1990, Pub. L No. 101-508, § 4601, 104 Stat 1388, 1388-166. Second, it per-
mitted states to expand eligibility for low-income pregnant women and infants with
family incomes between 133 and 185 percent of the poverty line. See 42 U.S.C.A. §
1396a(e) (West Supp. 2000). Third, it requires states to ultimately cover all children
with family incomes below 100 percent of the poverty line. See 42 U.S.C.A. §
1396a(l)(2)(C) (West Supp. 2000). Fourth, it required states to cover all medically
necessary care required by a Medicaid-eligible child under the early and periodic
screening, diagnosis, and treatment (EPSDT) program, even if such services were not
covered for adults. See 42 U.S.C.A. § 1396a(a)(43) (West Supp. 2000). Fifth, it re-
quired states to provide all services required by pregnant women for treatment of
conditions that "might complicate pregnancy." See 42 U.S.C.A. § 1396a(a)(10)(G)
(West Supp. 2000).
Repeal of these requirements continued to be a priority of the states. See
NATIONAL GOVERNORS' AsSOCIATION, POLICY POSITIONS: FEBRUARY 1998, Policy
EC-8.3.4 (effective Winter meeting 1997 to Winter meeting 1999) (copy on file with
author). "Under current policy, states have no ability to limit the range or cost of
services required in the EPSDT program. This open-ended requirement is driving up
the cost of the Medicaid budget at uncontrollable rates." Id.; see also National Con-
ference of State Legislatures, Health: Goals for State Federal Action (July 1998)
(copy on file with author). "Under current law, states are required to provide EPSDT
to children in the Medicaid program. States are required to treat any condition diag-
nosed during the screening, even if the procedure or service is not covered under the
state's Medicaid plan. This compromises the ability of the states to limit the range or
costs of Medicaid services." Id.
109 Section 1115 of the Social Security Act (42 U.S.C. § 1315 (1994))
authorizes the Secretary of Health and Human Services to waive requirements of
federal law in order to permit states to engage in experimental projects that are likely
to assist in promoting the objectives of the Medicaid program. See Vernellia Randall
et al., Section 1115 Medicaid Waivers: Critiquing the State Applications, 26 SEON
HALL L. REV. 1069 (1996). "Congress intended to permit projects that would help
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eluding waivers that were denied by other administrations. 110 It
is, at best, conjecture to suggest that the reason that the Clinton
Administration singled out prescribed drugs for a well-
publicized confrontation with the states related to the role
played by Vernon Jordan in working on this legislation as a
lobbyist for the pharmaceutical manufacturers."
I
'
However, despite claims of fiscal catastrophe, it does seem
clear that if this drug did not involve sexual expression, it
would not have been sin-led out for exclusionary treatment by
state Medicaid agencies.l2 It is revealing that, in covering this
improve the programs for beneficiaries ... A basic premise of the waiver is the ability
of states to assure cost neutrality for the federal government, reduce health care costs
for the state, and increase services without reducing quality. State waivers have often
been developed as a part of a larger state insurance reform." Id. at 1074-75.
1I See Medicare & Medicaid Guide (CCH), supra note 102; see also Kitzha-
ber & Gibson, supra note 102. See generally Garvey, supra note 102, at 586; Roggin,
supra note 102.
1,1 Vernon Jordan became one of the most powerful persons in Washington
during the Clinton Administration after chairing the Clinton Transition Team. See
Mark Fisher, First Friend: Vernon Jordan is a Man Comfortable with Power. And
With Hinsel/ WASH. POST, Jan. 27, 1998, at El. After a decade as Executive Direc-
tor of the National Urban League, Jordan became a partner at Aldn, Gump, Strauss,
Hauer & Feld, where he lobbied on behalf of drug companies and other clients. See
Dan Balz, Weight of Clinton's Problems Tests Strength of Advisers' Loyalty, WASH.
POST, Feb. 22, 1998, at A20. This was true despite the absence of Jordan's name on
lobbying reports required under the Lobbying Disclosure Act of 1995. See J. Gregory
Sidak, Review Essay, The Pett) Larceny of the Police Power, 86 CAL. L. REv. 655,
665 (1998) (reviewing FRED S. MCCHESNEY, MONEY FOR NOTHING: POLITICIANS,
RENT EXTRACTION, AND POLITICAL EXTORTION (1997)).
As discussed supra notes 45-72 and accompanying text, section 1927 had its
roots in legislation proposed by Senator David Pryor of Arkansas. See Lobbying Dis-
closure Conference Report, 140 CONG. REC. S13,945, 13,949 (daily ed. Oct. 3, 1994)
(statement of Sen. Levin). In 1990, Pryor suggested that "the Medicaid program
could save $300 million a year by adopting the same discount drug-buying strategies
used at a number of hospitals and national health maintenance organizations." Chris-
topher Drew & Michael Tackett, More and More, Lobbyists Call Shots in D.C., Cm.
TRIB., Dec. 6, 1992, at I. The drug lobby hired Vernon Jordan to help recruit black
and Hispanic groups willing to denounce the idea. See id. As described in the article,
"[the leaders of one black organization then sent out their own letters claiming that
[Senator] Pryor's plan [to reduce reimbursement to drug manufacturers] represented
the kind of approach used whenever 'mean-spirited bigots want to strike at the black
underclass.' Id. at 15. A spokesman for the Pharmaceutical Manufacturers Associa-
tion (now the Pharmaceutical Research and Manufacturers Association, PhARMA)
was quoted as denying that the group was "exploiting any racial aspect" of the issue.
Id.
112 The resistance of health insurers to covering matters of sexual and repro-
ductive health is not limited to government health insurance programs. See Hazel
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issue, the Associated Press wire story described the issue in the
following terms: "The blue, diamond-shaped potency pill from
Pfizer, Inc. has forced several states to weigh the importance of
sex against other pressing public policy concerns that require
funding."'1 3 The use of loaded language to frame the issues was
evident in the differing use that newspapers made of the Asso-
ciated Press story.114 Editorials also emphasized that if poor
people wanted to have fun, they should stop being poor. 115 This
attitude was exacerbated by the queasiness with which many
people approach the topic of sex and the elderly or disabled.
1 16
IX. SECTION 1927 AND COVERAGE OF VIAGRA
It is against this legal, political, and social backdrop that
the current dispute over Medicaid coverage of Viagra must be
analyzed. 117 If States have discretion to not include prescribed
Glenn Beb, Sex, Sexual Pleasure, and Reproduction: Health Insurers Don't Want
You to Do Those Nasty Things, 13 Wis. WOMEN'S L.J. 119 (1998).
113 John Hendren, 10 States Paying for Viagra for Poor, DAYTON DAILY
NEWs, May 8, 1998, at 5A; see also John Hendren, States Differ Over Extent Medi-
caid Should Provide New Impotency Pill, BuFFALo NEws, May 8, 1998, at 14A.
114 Compare John Hendren, Medicaid Viagra Coverage Not Available in
Some States: Insurers are Denying, Limiting Benefits for Impotence Treatment,
SEATTE TIMmEs, May 9, 1998, at A3 ("While Alabama and Florida allow the impov-
erished impotent four Viagra pills per month ....") (emphasis added) with Yep,
Florida's One of 10 States Giving Viagra to Impotent Poor, PRFSs J., May 8, 1998, at
D1 ("While Alabama and Florida allow the impoverished impotent four state-funded
liaisons a month... .") (emphasis added).
11"5 See Editorial, Free Love? States Shouldn't Have to Pay for Viagra,
COLUMBUS DISPATCH, Aug. 29, 1998, at A14 (criticizing the federal mandate of "free
whoopee at taxpayers' expense").
116 One of the few voices to the contrary was provided by Joe Gelarden, Much
Ado Over $10 Pill, INDIANAPOLiS NEws, Oct. 16, 1998, at CI. "Maybe [the furor] is
because the baby boomers and blonds under 35 think intimacy is only for the young,
flat-tummied, firm-breasted, strong-armed, thick-haired folks who turn up their noses
at the idea of sex after 40, or 50, or 60, or older." Id. Another rational voice was pro-
vided by Elizabeth S. Lawton, Commissioner of the Bureau for Medical Services of
the West Virginia Department of Health and Human Resources. See Elizabeth S.
Lawton, Medicaid Has to Pay for Viagra; Congress Limits Wlhat States May Refuse
to Provide, CHARLESTON DAILY MAIL, May 28, 1998, at 4A. "While it may seem
appropriate to some to challenge Medicaid's limited coverage of the impotence drug
Viagra, such an argument is based on several fallacies and faulty presumptions and
serves no purpose but to perpetuate the negative perception of West Virginia's Medi-
caid program held by those unfamiliar with the complexities of the Medicaid system
and the external forces that drive it." Id.
117 This is admittedly not the only dispute involving Viagra. Some have ar-
gued that providing insurance coverage of Viagra, a "male" drug, while coverage of
female oral contraceptives is excluded, constitutes sex discrimination. See ACOG
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drugs at all in their State plans, why could they not choose to
exclude Viagra from coverage? If States have wide discretion to
limit the amount, duration, and scope of required and optional
services, why could they not choose to exclude Viagra from
coverage or to greatly limit its availability to Medicaid benefi-
ciaries?
There are, therefore, two parts to any inquiry regarding
Medicaid coverage of a care or service. First, is the care or
service generally reimbursable in the state plan? Second, if the
care or service is generally reimbursable, is it reimbursable for
this particular beneficiary under these particular circumstances?
The answer to the first question is rather easy with regard to
Viagra; the second question is far more complicated to answer.
Pfizer, Inc., the manufacturer of Viagra, has executed a re-
bate agreement with the federal government that covers
Viagra.! 8 Since it has a rebate agreement in effect that covers
state Medicaid programs, 1 9 section 1927 is triggered and
Exposes Gender Bias of Viagra Coverage, FEMINIsT NEws (Feminist Majority Foun-
dation) (May 12, 1998) <http:lwww.ferinist.orglnewslnewsbytelmay98/05l2.htm>
(reporting the view of the American College of Obstetricians and Gynecologists); see
also Equity in Prescription and Contraception Coverage Act, 144 CoNG. REC. S4772
(daily ed. May 13, 1998) (statement of Senator Reid); Kathleen O'Connor and Mar-
garet Heldring, Viagra and Contraceptives: Gender Equity, SEATTLE TIMES, July 20,
1998, at B5. However, these arguments are inapplicable to the issue of Medicaid
coverage of Viagra since oral contraceptives and other family planning supplies are a
required service in all state Medicaid plans. See 42 U.S.C.A. § 1396d(a)(4)(C) (West
Supp. 2000) (providing in the definition of medical assistance "family planning
services and supplies (directly or under arrangements with others) to individuals of
child-bearing ... age who are eligible under the State plan"); see also Diane Lore,
Insurers Slow to See Benefits of the Pill, ATLANTA J., May 9, 2000, at C1 (describing
Georgia state law requiring insurance plans to cover the cost of contraceptives if they
cover other prescriptions such as Viagra). Others have questioned the "medicaiza-
tion" of sexuality and the impact of health care provider and drug company profits,
especially on female sexual dysfunction. See Meika Loe, Female Sexual Dysfimc-
fion: For Women or for Sale?, NETWORK NEws (National Women's Health Network,
Wash., D.C.), Jan.-Feb. 2000, at 1, 6.
11 Telephone interview by Sandra Lee with Jim Roper, Government Con-
tracts, Pfizer, Inc. (Oct. 20, 1999) (notes from telephone interview on file with
author); Telephone interview by Sandra Lee with Dennis Tolbert, National Accounts
for Contracting, Pfizer, Inc. (Oct. 20, 1999) (notes from telephone interview on file
with author). Because the rebate agreement contains proprietary information, Pfizer
representatives declined to make a copy of the actual rebate agreement available.
The confidentiality of these rebate agreements is protected under section
1927(b)(3)(D) of the Social Security Act. See 42 U.S.C.A. § 1396r-8(b)(3)(D) (West
Supp. 2000).
19 A copy of the form rebate agreement between the Secretary of Health and
Human Services and pharmaceutical manufacturers is on file with the author. This
2001]
HEALTH MATRIX
Viagra must be included in State Medicaid plans. However,
inclusion of a drug in a State Medicaid formulary is not the
same as making that drug available to all patients, at all times.
under all circumstances. Access to Viagra may then potentially
be controlled through three techniques: (I) limits on amount,
duration, and scope of services imposed before Viagra is pre-
scribed; (2) prior authorization requirements as Viagra is pre-
scribed for a particular Medicaid beneficiary; and (3) utilization
review of treatment decisions to prescribe Viagra to a particular
Medicaid beneficiary after it is dispensed.
A. Limits on Amount, Duration, and Scope
Since the inception of the Medicaid program in 1965, states
have been authorized by federal law to impose limits on the
amount, duration, and scope of services provided to Medicaid
beneficiaries. 12 1 The "amount, duration, and scope" requirement
form agreement was initially proposed as Medicaid: Prescription Drug Rebate
Agreement. See Medicaid Program; Drug Rebate Agreement, 56 Fed. Reg. 7049,
7050-54 (1991).
120 None of the exclusions in section 1927 is applicable to Viagra. Viagra is
not an agent used for anorexia, weight loss, or weight gain; an agent used for cos-
metic purposes or hair growth; an agent used for the symptomatic relief of cough and
colds; an agent used to promote smoking cessation; a prescription vitamin and min-
eral product; a nonprescription drug; a covered outpatient drug which the manufac-
turer seeks to require as a condition of sale that associated tests or monitoring serv-
ices be purchased exclusively from the manufacturer or its designee; a barbiturate; or
a benzodiazepine. See 42 U.S.C.A. § 1396r-8(d)(2) (West Supp. 2000) (listing the
classes of drugs subject to restriction). The only exclusion that some have argued is
applicable is the exception for "agents when used to promote fertility." 42 U.S.C.A.
§ 1396r-8(d)(2)(B) (West Supp. 2000); see also Medicaid Coverage of Viagra, AFI
HEALTH COMMITrEE REP. (National Conference of State Legislatures, Wash., D.C.)
July 1998, at 1. This argument was, of course, rejected by HCFA.
121 See 42 C.F.R. § 440.230 (1999), supra note 43. This section was promul-
gated in 1981 after the split of the Department of Health, Education, and Welfare into
the Departments of Education and Health and Human Services in 1979. See Medicaid
Eligibility and Coverage Criteria, 46 Fed. Reg. 47,993 (1981) (The Department of
Health, Education, and Welfare was redesignated as the Department of Health and
Human Services by Pub. L. No. 96-88, tit. V, § 509, 93 Stat. 695 (1979)). However,
the language essentially repeated the regulatory requirements in place from 1966 to
1981. See 42 C.F.R. § 440.230 (1979); 45 C.F.R. § 249.10 (1974).
Although this section is based on the authority of section 1102 of the Social
Security Act (42 U.S.C. § 1302), it implements 42 U.S.C. § 1396a(a)(10) (1994):
A state plan for medical assistance shall provide...
(B) that the medical assistance made available to any individual described
in subparagraph (A) [the categorically needy] -
(i) shall not be less in amount, duration, or scope than the medical assis-
tance made available to any other such individual, and
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has been the subject of substantial litigation since 1965.122 Al-
though the United States Supreme Court has interpreted certain
aspects of the "amount, duration, and scope" requirement, 123 it
has never ruled on the level of medical care and services that is
(ii) shall not be less in amount, duration, or scope than the medical as-
sistance made available to individuals not described in subparagraph
(A);
(C) that if medical assistance is included for any group of individuals de-
scribed in section 1396d(a) [section 1905 of the Social Security Act] who
are not described in subparagraph (A) or (E), then -
(i) the plan must include a description of (I) the criteria for determining
eligibility of individuals in the group for such medical assistance, () the
amount, duration, and scope of medical assistance made available to indi-
viduals in the group ....
42 U.S.C. § 1396a(a)(10)(B), (C) (1994).
122 The first major case upholding limits on the amount, duration, and scope
of Medicaid services was District of Columbia Podiatry Soc'y v. District of Colum-
bia, 407 F. Supp. 1259 (D.C. 1975). This was followed in rapid succession by Vir-
ginia Hosp. Ass'n v Kenlev, 427 F. Supp. 781 (E.D. Va. 1977) (upholding Virginia's
21-day limit on coverage of inpatient hospital services); Dodson v. Parham, 427 F.
Supp. 97 (N.D. Ga. 1977) (invalidating Georgia's restrictive prescription drug for-
mulary); Beal v Doe, 432 U.S. 438 (1977) (upholding Pennsylvania's exclusion of
coverage of abortion services that were not medically necessary); Curtis v. Taylor,
625 F.2d 645 (5th Cir. 1980) (upholding Florida's limitation of coverage of physi-
cian's services to three visits per month); Charleston Mem'l Hosp. v. Conrad, 693
F.2d 324 (4 h Cir. 1982) (upholding South Carolina's 12 days per year limitation on
impatient hospital services and 18 visits per year limitation on outpatient services);
Meyers v. Reagen, 776 F.2d 241 (8th Cir. 1985) (invalidating Iowa's exclusion of
electronic speech devices from coverage); Ledet v. Fischer, 638 F. Supp. 1288 (M.D.
La. 1986) (invalidating Louisiana's limitation on coverage of eyeglasses to post-
cataract surgery patients); Cowan v. Myers, 232 Cal. Rptr. 299 (Ct. App. 1986) (up-
holding California's limitation on "medically necessary" services to those "reasona-
bly necessary to protect life, to prevent significant disability or illness, or to alleviate
severe pain"); Weaver v. Reagen, 886 F.2d 194 (8th Cir. 1989) (invalidating Mis-
souri's exclusion of azidothymidine to treat certain diagnoses or conditions); Visser v.
Taylor, 756 F. Supp. 501, 506 (D. Kan. 1990) (invalidating the Kansas exclusion of
Clozaril from Medicaid coverage); Sobky v. Smoley, 855 F. Supp. 1123 (E.D. Cal.
1994) (enjoining California to provide sufficient methadone treatment services);
Hope Med. Group for Women v Edwards, 63 F.3d 418 (5th Cir. 1995) (invalidating
Louisiana's exclusion of certain medically necessary abortions); Hem v. Beye, 57
F.3d 906 (10th Cir. 1995) (invalidating Colorado's exclusion of certain abortions
resulting from rape or incest); Kirk v. Dunning, 370 N.W.2d 113 (Neb. 1985) (invali-
dating Nebraska's exclusion of periodontal services); DeSario v. Thomas, 139 F.3d
80 (2nd Cir. 1998) (upholding Connecticut's limits on coverage of durable medical
equipment); and Smith v Palmer, 24 F. Supp. 2d 955 (N.D. Iowa 1998) (invalidating
Iowa's exclusion of sex reassignment surgery).
1- These interpretations have occurred mostly in the context of restrictions on
Medicaid funding for abortion services. See Beal v. Doe, 432 U.S. 438 (1977) (up-
holding refusal by the Commonwealth of Pennsylvania to pay for non-therapeutic
abortions under the State's medical assistance program).
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necessary to satisfy this requirement. 124 In the meantime, we are
left with a conflict between the circuits as to the extent to which
states are required to cover all medically necessary care and
services when that care or service is included in the State Medi-
caid plan. 125 At a minimum, States are required to provide an
item of care or service in sufficient amount, duration, and scope
to meet the needs of most recipients. 126 At most, States are re-
124 In Alexander v. Choate, 469 U.S. 287 (1985), the Supreme Court upheld a
Tennessee reduction on Medicaid coverage of inpatient hospital days from 20 to 14
days per fiscal year against a challenge under section 504 of the Rehabilitation Act of
1973 (29 U.S.C. § 794). The Supreme Court observed that the District Court had
found that "the 14-day limitation would fully serve 95% of even handicapped indi-
viduals eligible for Tennessee Medicaid . I..." d  at 303. Although that language
sounds like the standard used in such cases as Curtis v Taylor and Virginia Hospital
Association v. Kenley, the Supreme Court went on to declare, "[b]ecause that conclu-
sion is unchallenged, we express no opinion on whether annual limits on hospital care
are in fact consistent with the Medicaid Act." Id. at 303 n.23.
125 This conflict is highlighted by the decisions of the Court of Appeals for the
Eighth Circuit in Weaver v Reagen, 886 F.2d 194 (8th Cir. 1989) and of the Court of
Appeals for the Fifth Circuit in Curtis v. Taylor, 625 F.2d 645 (5th Cir. 1980). In
Weaver, the Court of Appeals held that the State of Missouri could not deny Medi-
caid coverage of AZT for AIDS patients whose doctors determined that administra-
tion of the drug was medically necessary. By contrast, in Curtis, the Court of Ap-
peals held that Florida could deny medically necessary physician care to patients who
required more than three doctor visits per month.
126 This standard was probably first clearly enunciated in Virginia Hosp. Ass'n
v. Kenley, 427 F. Supp. 781 (E.D. Va. 1977). In this case, the district court upheld a
Virginia Medicaid regulation limiting coverage of inpatient hospital services to 21
days. See id. at 784. The trial court acknowledged that such a limit would result in the
denial of medically necessary care for at least some recipients. See id. at 785 (con-
ceding that "[uinquestionably, there are Medicaid recipients in Virginia who require,
as a matter of medical necessity, more than 21 days of hospitalization").
In Kenley, Judge Merhige noted that the decision came down to the proper
construction of the federal "amount, duration, and scope" regulation (then found at 45
C.F.R. § 249.10(a)(5)(i)) and, specifically, what is meant by the language that the
services must be sufficient "to reasonably achieve their purpose." Id. As explained by
the Court, "(the answer to this query lies in which such language is interpreted to
mean the services must be sufficient to reasonably achieve their purpose for an indi-
vidual patient or sufficient to reasonably achieve the purpose of the provision of that
type of service to the Medicaid population as a whole." Id. The Court noted that the
"Department of Health, Education and Welfare has interpreted this regulation to
mean that services provided reasonably achieve their purpose if the amount, scope
and duration would be sufficient for most persons needing that type of care." Id. at
785-86. The Secretary of Health, Education and Welfare was a party to the Kenley
litigation. Subsequently, he relied on an HEW Memorandum stating that, "For exam-
ple, if a state wishes to limit days of hospital care per year, the number of days should
be at least adequate to cover one admission for the average days needed by those
individuals covered under the program." Id. at 786 (quoting HEW Field Staff Infor-
mation and Instruction Series: FY-76-62, at 7 (Jan. 2, 1976)).
224 [Vol. 1 1:189
MEDICAID AND VIAGRA
quired to cover all medically necessary use of an item of care or
service included in the State plan. 127 In many circuits, the stan-
dard is, at best, unintelligible.?
21
Among the cases following the approach of Judge Merhige in Kenley are
Curtis v. Taylor, 625 F.2d 645 (5th Cir. 1980) and Charleston Mern'l Hosp. v.
Conrad. 693 F.2d 324 (4th Cir. 1982). In these cases, the Courts of Appeals upheld
limits on inpatient and outpatient hospital coverage that met the medical needs of
most of the eligible Medicaid recipients.
127 Probably the best example of a jurisdiction in this category is the Eighth
Circuit. In Weaver v. Reagen, 886 F.2d 194 (8th Cir. 1989), the United States Court
of Appeals for the Eighth Circuit invalidated a Missouri Medicaid regulation limiting
coverage of AZT (Zidovudine, or Azidothymidine) to those patients with a "medical
diagnosis of acquired immunodeficiency syndrome (AIDS) and who have a history of
cytologically confirmed Pneumocystis carinil pneumonia (PCP) or an absolute CD4
(T4 helper/inducer) lymphocyte count of less than two hundred (200) per cubic mil-
limeter in the peripheral blood before therapy is begun." Id. at 196.
Although the Missouri regulation paralleled the FDA approval statement for
the drug, numerous physicians in Missouri were prescribing AZT for patients who
did not meet the FDA criteria in order to prevent or retard the progression of the dis-
ease to a more serious illness. See id. at 196-97. The Court acknowledged that this
off-label use deviated from the conditions for which the drug was approved but ex-
plained that, "[aiccepted medical practice often includes drug use that is not reflected
in approved drug labeling." Id. at 198 (citing Use of Approved Drugsfor Unlabeled
Indications, 12 FDA DRUG; BULL. 4 (April 1982)). Reaffirming its prior holding in
Pinneke v Preisser, 623 F.2d 546 (8th Cir. 1980), the Court stated, "[t]he decision of
whether of not certain treatment or a particular type of surgery is 'medically neces-
sary' rests with the individual recipient's physician and not with clerical personnel or
government officials." Id. at 199 (citing Pinneke, 623 F.2d at 550). Missouri, there-
fore, could not deny coverage of AZT to AIDS patients who were eligible for Medi-
caid and whose physicians certified that AZT was medically necessary treatment. See
id. at 200.
123 For example, in the Third Circuit, it appears that Medicaid agencies must
cover all medically necessary care, but the legal analysis is at best muddled. In IVhite
v Beal, 413 F. Supp. 1141 (E.D. Pa. 1976), the district court considered the validity
of a Pennsylvania regulation limiting coverage of eyeglasses to those persons with
"eye pathology:' Id. at 1152. The district court invalidated the restriction on several
grounds. The Court first held that the restriction violated the first criterion of 45
C.F.R. § 249.l0(a)(5)(i) because it did "not provide the amount, scope and duration
of services necessary to achieve the purposes stated in the regulations, viz., to im-
prove vision:' Id. at 1153. Although this conclusion is probably legally correct, the
Court did not evaluate the extent to which the provision of eyeglasses met the needs
of some Medicaid recipients.
The Court then went on to hold that the Pennsylvania restriction violated the
second criterion on 45 C.F.R § 249.10(a)(5)(i) because it "arbitrarily den[ied] re-
quired services to the categorically needy solely because of a condition - refractive
error." Id. at 1154. While it is true that the Pennsylvania restriction distinguished
based on "the diagnosis, type of illness or condition," that standard only applies "to
the required services for the categorically needy:' 45 C.F.R. § 249.10(a)(5)(i) (1974)
(emphasis added). However, eyeglasses were (and are) an optional service for the
categorically needy. See 42 U.S.C. § 1396d(a)(12) (1994). The clause prohibiting
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discrimination on the basis of "the diagnosis, type of illness or condition," relied on
by the district court as an alternate ground for its holding there did not even apply to
the Pennsylvania restriction at issue. The district court obscured this point by adding
ellipses to its quotation of the relevant section of 42 C.F.R. 249.10(a)(5)(i) ("With
respect to the required services for the categorically needy... .") and by relying on
the phrase that is often a red flag to readers: "It is clear that eyeglasses are a required
service to the categorically needy under the Pennsylvania plan." White, 413 F. Supp.
at 1154 (emphasis added).
The version of the amount, duration and scope regulation in effect at the time
of White v. Beal was promulgated in 1974. See Implementation of Social Security
Amendments of 1972 and 1973, 39 Fed. Reg. 16,969 (1974). That permutation of the
regulation contained the following text eliminated in the Court's citation of the sec-
tion: "With respect to the required services for the categorically needy (subparagraph
(1) of this paragraph) and the medically needy (subparagraph (2) of this subpara-
graph), the State may not arbitrarily deny or reduce the amount, duration, or scope of
such services to an otherwise eligible individual solely because of the diagnosis, type
of illness or condition." 45 C.F.R. 249.10(a)(5)(i) (1974) (as promulgated at 39 Fed.
Reg. 16,969, 16,971 (1974)) (emphasis added). The language "subparagraph (I) of
this paragraph" refers to "the first five items of medical and remedial care and serv-
ices, as set forth in paragraph (b)(1) through (5) of this section ... ." 45 C.F.R.
249.10(a)(I) (1974). Nowhere in paragraphs (b)(1) through (5) is there any mention
of eyeglasses. In fact, eyeglasses only appear as a service in subparagraph (b)(12)
making it a service for the categorically needy that could be restricted, consistent
with the Medicaid statute, on the basis of diagnosis, type of illness or condition. See
45 C.F.R. § 249.10(b)(12) (1974). Similarly, for the medically needy, subparagraph
(2) of that paragraph requires states to provide either "[t]he first five items as set forth
in paragraph (b)(1) through (5) of this section" or "[a]ny seven of the items as set
forth in paragraph (b)(1) through (16) of this section .... ." 45 C.F.R. §
249.10(a)(2)(i) & (ii) (1974) (promulgated at 39 Fed. Reg. 10,971). At the time of
White v. Beal, Pennsylvania did not provide only the minimum number of services
enumerated in 45 C.F.R. 249.10(a)(2). Therefore, the provision of eyeglasses was not
required for the medically needy and the provision of eyeglasses could be limited,
consistent with the Medicaid statute, on the basis of diagnosis, type of illness or con-
dition. See id.
In each of these clauses, I have purposefully inserted the words "consistent
with the Medicaid statute." While the district court in White v. Beal got it wrong in
interpreting Medicaid regulations as it did, its conclusion was arguably also required
by section 504 of the Rehabilitation Act of 1973. See generally 29 U.S.C.A. § 794
(West 1999 & Supp. 2000) (prohibiting discrimination based on disability by any
federally funded program).
Although the district court got its analysis at least half-right, the Court of
Appeals for the Third Circuit could not take even that much credit. In affirming the
decision of the district court, the Court of Appeals based its decision solely on the
ground that, "[tihe regulations permit discrimination in benefits based upon the de-
gree of medical necessity but not upon the medical disorder from which the person
suffers." White v. Beal, 555 F.2d 1146, 1152 (3rd Cir. 1977). Reaching even further,
the Court of Appeals suggested that once a state includes an optional service in its
state plan, that service loses its character as an "optional" service and becomes a
"required" service for purposes of 45 C.F.R. 249.10(a)(5)(i). See id. at n.6 (stating
interpretation of regulation by the Regional Commissioner for Social and Rehabilita-
tive Services, HEW). The Court therefore rejected the analysis of the scope of the
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Such states as New York have limited the amount, duration,
and scope of Viagra coverage. 129 In New York, Medicaid bene-
ficiaries are limited to a maximum of six tablets per 30 days.
130
States like New York have therefore probably met the require-
ments of section 1927 by including Viagra as a covered pre-
scription drug in their Medicaid formularies without covering
all medically necessary use of the drug.1 3
1
In her letter to State Medicaid Directors dated November
30, 1998, Sally Richardson, Director of the Center for Medicaid
and State Operations, of the Health Care Financing Administra-
tion, stated that, "the law requires that a State's Medicaid pro-
gram cover Viagra when medical necessity dictates such cover-
age for the drug's medically accepted indication."' 132 Taken lit-
erally, that language would impose an obligation on the States
regulation provided by the Regional Commissioner for Social and Rehabilitative
Services of HEW in Philadelphia and the plain language of the regulation. See id.
That error has been repeated by many casual readers of the Medicaid regulations. See
Stewart, supra note 44, at 616 (stating that the amount, duration, and scope regulation
prohibits states from denying coverage of a prescription drug based upon type of
illness or condition).
129 See Letter from Gregor N. Macmillan, supra note 100, at 1; see also New
York Dep't of Health, supra note 100. Several other states have imposed similar
limits on the amount of Viagra that will be covered. For example, Florida has placed
a limit of four Viagra tablets per month that a Medicaid recipient may receive. See E-
mail from Gary Crayton, Director of Medicaid, Florida Agency for Health Care
Admin., to Leidys Dominguez, Research Assistant (July 16, 1999) (copy on file with
author); see also table ifra Appendix A (identifying the states' Medicaid coverage
plans for Viagra).
"o See Letter from Gregor N. Macmillan, supra note 102; see also New York
Dep't of Health, supra note 102.
A' This statement assumes that New York has empirical evidence to show
that six tablets of Viagra meet the needs of most Medicaid beneficiaries. New York
also imposes certain substantive requirements controlling access to Viagra. Viagra
can only be prescribed after a physical examination and prescribers must maintain
documentation of this examination. A diagnosis of erectile dysfunction is required
and the patient must not have a history of using nitrates or any drug containing ni-
trates within the past 180 days. Prescriptions may be issued for a one-month supply
with a maximum of two refills and subsequent prescriptions require a new physical
examination by the prescriber. Unlike some other prescribed drugs, early refills and
vacation supply requests will not be honored. See New York Dep't of Health, supra
note 102.
""
2 See Letter from Sally K. Richardson, supra note 99, at 1. The issue of the
scope of coverage of Viagra in public and private health insurance plans has been the
subject of litigation. See Michael Grunwald, U.S. Judge Asserts Need for More
Viagra C'overage. WASH. PosT, Mar. 27, 1999, at A3 (noting that Judge filed a class
action suit against HMO claiming it had a duty to cover Viagra as "medically neces-
sary").
20011
HEALTH MATRIX
to pay for Viagra in anpy situation in which it is being used for
its approved purpose. States like New York could not impose
an across-the-board six tablets per 30 days limit since some
Medicaid beneficiaries might be able to demonstrate a medical
need for perhaps eight tablets per 30 days. 134 The New York
limit, therefore, squarely presents the question of whether denial
of a medically necessary dosage is legally permissible. 135
B. Prior Authorization
Another way in which utilization of an item of care or
service is controlled is by subjecting the care or service to prior
authorization. 136 Under a prior authorization system, a provider
133 Occasionally, prescription drugs approved by the FDA are prescribed by
health care professionals for purposes other than their approved uses. Such a practice
is referred to as off-label use. See An Off-Label Update: Prescribing Drugs for Un-
approved Uses, PEOPLE'S MED. SoC'Y NEWSL, June 1, 1999, at I (People's Med.
Soc'y, Allentown, Pa.); Michael F. Conlan, Off-Label, Off-Base: Physicians are Get-
ting Unapproved-Use Data from Manufacturers that is Denied to Pharmacists, DRUG
ToPics, Feb. 15, 1999, at 57; Meg Stevenson, Prescriptions: When They're Good for
More Than One Ailment, ACCENT ON LIvING, Fall 1998, at 42; FDA: To Ease 'Off-
Label' Use Restrictions, AM. HEALTH LINE, June 8, 1998; Off-Label Use of Drugs an
Issue, CHAIN DRUG REV., Jan. 20, 1997, at Rx6; Diane Debrovner, Off-Label on
Trial, AM. DRUGIST, Nov. 1994, at 26. The FDA has attempted to restrict the unap-
proved uses of approved drugs by prohibiting manufacturers from describing these
off-label uses. See Fran Kritz, FDA Seeks to Add Drugs' New Uses to Labels, WASH.
POST, Mar. 29, 1994, at ZI 1. Despite this effort, M. Roy Schwarz, a physician and
vice-president of science and education for the American Medical Association, esti-
mated that off-label prescribing makes up 40 to 60 percent of all drugs prescribed.
See id. Most recently, FDA restrictions on the ability of drug manufacturers to de-
scribe off-label uses to health care professionals was challenged and invalidated. See
also Washington Legal Found. v. Henney, 56 F. Supp. 2d 81, 87 (D.D.C. 1999)
(holding that the Food and Drug Administration Modernization Act and its imple-
menting regulations unconstitutionally restrict protected commercial speech of drug
manufacturers).
114 In her letter to State Medicaid Directors, Sally Richardson proposed sev-
eral measures to control costs, including "plac(ing] limits on the number of refills or
the quantity per prescription to discourage waste, fraud, and abuse." Letter from Sally
K. Richardson, supra note 99, at 2. Absolute limits were not suggested, however. See
id.
135 New York is by no means unique in imposing limits on the availability of
Viagra. See table infra Appendix A. According to Dr. Mike Magee, Senior Medical
Advisor for Pfizer, "[State limits] vary all the way from a low of Georgia, three a
month, to unrestricted. Most of them [the states] are coming in at the level of six to
eight [tablets per month]." Transcript of Pennsylvania Hearing, supra note 36, at 31-
32.
136 In her letter, Sally Richardson urged states to "[e]stablish prior authoriza-
tion programs to assure that health professionals meet their responsibilities in pre-
scribing Viagra...." Letter from Sally K. Richardson, supra note 99, at 2.
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of care or service would have to obtain approval from the State
Medicaid agency before providing that care or service to a par-
ticular patient. Since most Medicaid State agencies now have
fully-computerized management systems, 137 a provider ordinar-
ily must obtain an authorization number to override a computer
edit that would otherwise deny payment for the care or service.
Such systems ordinarily require some action by a human
being. Since State Medicaid agencies strive to keep personnel
costs (and administrative costs generally) to a minimum, a prior
authorization model could be utilized for a drug like Viagra.
However, because of such costs, use of a prior authorization
system will generally be limited to costly services if some non-
discretionary model can be utilized.
Section 1927 imposes additional requirements on a State
wishing to subject Viagra to prior authorization. 3 8 Such a sys-
tem must provide a "response by telephone or other telecommu-
nication device within 24 hours of a request for prior authoriza-
tion." 139 Such a system must also "provide[] for the dispensing
of at least a 72-hour supply of a covered outpatient prescription
drug in an emergency situation.... 140
C. Utilization Review
Utilization review is another way in which States can limit
access to care and services in State Medicaid plans. 141 Whereas
prior authorization takes place before an item of care or service
can be provided, utilization review usually takes place after the
117 See David F. Chavkin, An Introduction to the Medicaid Management In-
fonnation System (AfMIS), or Your Friend, the Computer, 12 CLEARINGHOUSE REV.
99, 102 (1978).
'sSee section 1927(d)(1)(A) and (d)(5) (42 U.S.C.A. §§ 1396r-8(d)(1)(A) &
(d)(5) (West Supp. 2000)).
'-19 Section 1927(d)(5)(A) (42 U.S.C.A. § 1396r-8(d)(5)(A) (West Supp.
2000)).
14' Section 1927(d)(5)(B) (42 U.S.C.A. § 1396r-8(d)(5)(B) (Vest Supp.
2000)).
141 Sally Richardson urged that states "[m]onitor and discipline, as appropri-
ate, providers who prescribe Viagra for medically inappropriate indicates or when not
medically necessary." Letter from Sally K. Richardson, supra note 99, at 2. Section
1396a(a)(30)(A) provides in relevant part that, a State plan for medical assistance
must "provide such methods and procedures relating to the utilization of, and the
payment for, care and services available under the plan (including but not limited to
utilization review plans as provided for in section 1903(i)(4) [42 U.S.C. §
1396b(I)(4)] as may be necessary to safeguard against unnecessary utilization of such
care and services ... " 42 U.S.C.A. § 1396a(a)(30)(A) (West Supp. 2000).
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delivery of that care or service. A provider and/or a beneficiary
may thereby be placed at risk for denial of reimbursement or
other sanctions after the care or service has been provided. 142
More and more, utilization review is also being done
through computer edits.143 New York has decided to employ
utilization review to control usage of Viagra under the State
Medicaid program. All prescriptions for Viagra are subjected to
"Drug Utilization Review (DUR)" to ensure that the patient is
not currently receiving any contra-indicated drugs. 144 Pfizer has
advised health care professionals that Viagra should not be ad-
ministered to patients using nitrates at any time.14 5 When a
claim for Medicaid reimbursement of Viagra for a patient is
submitted by a pharmaceutical provider, the computer system
would examine the patient's record for any prescriptions for any
drugs containing nitrates within the past 180 days.146 Reim-
bursement for Viagra would then be denied. 147 From a financial
standpoint, the State would save money on the non-reimbursed
prescription; from a medical standpoint, the patient might or
might not be protected from the contraindicated medication
142 While retroactive denial may pose due process issues, the mere fact of
retroactive denial after utilization review has been held not to be a per se due process
violation. See I-immler v. Califano, 611 F.2d 137 (6 Cir. 1979) (upholding retroac-
tive denial of coverage for nursing home care under the Medicare program); see also
Mathews v. Eldridge, 424 U.S. 319 (1976) (rejecting due process challenge to Social
Security Administration policy denying continuing assistance to former beneficiary
challenging termination of assistance).
143 The Surveillance and Utilization Review (SlUR) Subsystem of the Medi-
caid Management Information System (MMIS) maintains data on activities and char-
acteristics of individual Medicaid providers and recipients from submitted claims.
See Chavkin, supra note 137, at 102.
144 See Letter from Gregor N. Macmillan, supra note 102; see also New York
Dep't of Health, supra note 102, at 3.
145 "Important Prescribing Information" provided by Pfizer, Inc. to health care
professionals states that, "[c]onsistent with its known effects on the nitric ox-
ide/cGMP pathway ... VIAGRA was shown to potentiate the hypotensive effects of
nitrates, and its administration to patients who are using organic nitrates, either regu-
larly and/or intermittently, in any form is therefore contraindicated." Viagra.com.
supra note 32. Nitrates are found in many prescription medicines that are used to
treat angina (chest pain due to heart disease) as well as in recreational drugs such as
amyl nitrate ("poppers"). See Patient Summary of Information About Viagra, supra
note 32.
146 See Letter from Gregor N. Macmillan, supra note 102, at 1; see also New
York Dep't of Health, supra note 102.147 The denial might actually occur after the Viagra had been dispensed since
the computer clearance process does not always happen instantaneously.
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since the prescription would already have been dispensed and
probably consumed.1
48
X. CONCLUSION
The furor over Medicaid coverage of Viagra began to re-
ceive national attention when the battle lines were drawn be-
tween the federal government and the States in July 1998. Al-
though it was somewhat refreshing to see the federal govern-
ment unequivocally state that the Medicaid standards governing
prescription drugs required State coverage of Viagra, little was
done to actually compel compliance by the states with these
standards.' 49 Several States continue to flout the law.150 The
federal government did, at least, restore some potency to the
notion that there are a few absolute standards limiting State dis-
cretion in the Medicaid program. At the same time, State claims
of dire financial consequences and "unfunded mandates" have
proven to be grossly exaggerated and States have been able to
comply with federal law without threatening their financial
health.' 51 Ultimately, the tempest over coverage of Viagra has
proven to be much ado over very little.
148 Many pharmacies have their own computerized patient information sys-
tems to identify contraindications and side-effects. However, even such a system is
not foolproof since it would not reflect problems associated with drugs dispensed
through other pharmacies.
149 In effect, HCFA spoke loudly, but carried no stick. No compliance actions
were initiated pursuant to section 1396(c) against states that failed to comply with the
Medicaid requirements. See 42 U.S.C. § 1396(c) (1994) (delineating purported re-
quirements for operation of State plans).
'" See table infra Appendix A for a list of the states that, as of the date of the
survey, were still not covering Viagra in their state plans.
151 The warnings of some alarmists that the financial sky was literally falling
have proven to have little basis in fact. See Stewart, supra note 44, at 613-14. "These
[impoverished] states, with high percentages of Medicaid eligible persons, should
fight the directive through any measures possible to avoid the devastating cuts in
vital health programs that will be necessary to meet the demands for Viagra." Id.
(emphasis added).
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APPENDIX A: COVERAGE OF VIAGRA IN STATE
MEDICAID PLANS
Alabama Maximum of 4 tablets per month
and requires prior authoriza-
tion 52
Alaska Excluded from coverage1
53
Arizona No restrictions on quantity"
Arkansas Excluded from coverage l5
California Maximum of 6 tablets per 30
days'
56
Colorado Maximum of 6 tablets per 30
days and requires prior authori-
zation'
57
152 See Letter from Mary H. Finch, Legislative & Media Liaison, Alabama
Medicaid Agency, to Leidys Dominguez, Research Assistant (Sept. 15, 1999) (on file
with author). See also E-mail from John Searcy, Deputy Commissioner, to Leidys
Dominguez, Research Assistant (Sept. 15, 1999) (on file with author); Alabama
Medicaid Agency, Provider Notice No. 99-04 (last modified Jan. 27, 1999)
<http://www.medicaid.state.al.us/bulletin/notices/pn9904.htm> (on file with author);
Viagra Coverage: Oregon Says 'Yes,' But Not Alabama, supra note 102 (describing
efforts by Alabama to limit Medicaid coverage of Viagra).
'5 See E-mail from Robert B. Labbe, Alaska Medicaid Agency, to Leidys
Dominguez, Research Assistant (Sept. 15, 1999) (on file with author). The justifica-
tion put forward for this exclusion is that, "Viagra... is a drug which is used to treat
infertility." E-mail from David L. Campana, Pharmacy Program Manager, Alaska
Medicaid Agency, to Leidys Dominguez, Research Assistant (Sept. 15, 1999) (on file
with author).
'1 See E-mail from Nancy Northrup, Claims Policy Manager, Ariz. Health
Care Cost Containment Sys., to Leidys Dominguez, Research Assistant (Sept. 17,
1999) (on file with author); Letter from Leonard A. Jasinski, Medical Director, Ari-
zona Health Care Cost Containment Sys., to Leidys Dominguez, Research Assistant
(Sept. 16, 1999) (on file with author).
155 See E-mail from Ray Hanley, Arkansas Medicaid Agency, to Leidys
Dominguez, Research Assistant (Sept. 15, 1999) (on file with author); Official Notice
from Ray Hanley, Director, Arkansas Dep't of Hum. Serv., Div. of Med. Serv., to
Health Care Providers (July 22, 1998) (No. DMS-98-Q-4, DMS-98-R- 11, DMS-98-
E-7 (noting that "[u]ntil more information is available Medicaid is temporarily sus-
pending payment for Viagra, effective August 1, 1998") (on file with author); see
also Viagra: Arkansas Plans to End Medicaid Coverage, AM. HEALTH LINE, July 24,
1998.
156 See Letter from Katherine A. Cabacungan, Senior Consulting Pharmacist,
State of California Dep't of Health Serv., to Leidys Doinguez, Research Assistant
(Sept. 30, 1999) (on file with author).
1s7 See COLORADO MEDICAID PRIOR AUTHORIZATION CRITERIA, at 8 (1999)
(on file with author).
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Connecticut Maximum of 6 tablets per
month'55
Delaware Excluded from coverage 59
District of Columbia Maximum of 6 tablets per month
with prior authorization'
60
Florida Maximum of 4 doses per
month'
61
Georgia Maximum of 3 tablets per
month 62
Hawaii Excluded from coverage
6 3
Idaho Excluded from coveragel' 4
Illinois Maximum of 4 doses per month;
approval limited to 3 months'
65
158 See E-mail from David Parrella, Director, to Leidys Dominguez, Research
Assistant (Oct. 1, 1999) (on file with author).
"9 See E-mail from Phillip Soule, Medicaid Director, Delaware Dep't of
Health & Soc. Serv., to Leidys Dominguez, Research Assistant (Sept. 28, 1999) (on
file with author). In that message, Mr. Soule explains that Delaware excludes cover-
age on the ground that, "we have found no medically necessary reasons for the use of
Viagra." Id.
f6o Telephone conversation between Grace Mora, Research Assistant, and
Angie Reynolds, Program Assistance, Med. Assistance Admin. Office, Pharmacy
Dep't (Feb. 7, 2000).
161 See Agency for Health Care Admin., Medicaid Senices: Pharmacy Notes,
(visited July 7, 1998) <http:/lwww.fdhc.state.fl.us/medicaidlpharmacy/phamote.htm>.
"The simple fact is that federal statutes requiring the manufacturer to pay a rebate to
Medicaid also require all state Medicaid programs to cover this product." Id.; E-mail
from Gary Crayton to Leidys Dominguez, Research Assistant (July 16, 1999) (on file
with author). In an article describing the Florida coverage of Viagra, the State was
criticized for "allowling] the impoverished impotent four state-funded liaisons a
month ..... " Yep, Florida's One of 10 States Giving Viagra to Impotent Poor, supra
note 112. During the second quarter of 1998, the Florida Medicaid agency paid
$105,020 for about 4,000 Viagra prescriptions dispensed during that period. See In
Briefi Florida Medicaid, PINK SHEET, Nov. 16, 1998, at 28.
t62 See Lillian Lee Kim, 3 Per Month: Ga. Program to Buy Viagra, ATLANTA
J.- Cosr., Sept. 1, 1998, at C3 (indicating that Medicaid coverage will only be ex-
tended to males over age 21 with physician approval); Telephone interview by Leidys
Dominguez with Etta Hawkins, Georgia Medicaid Agency (Oct. 5, 1999) (transcrip-
tion on file with author).
163' Telephone conversation between Grace Mora, Research Assistant, and
Lynn Donovan, Pharmacy Consultant, Med-QUEST Div. (Feb. 8, 2000).
164 See E-mail from Angela Fink, Idaho Dep't of Health & Welfare, Admin.
Procedures Section, to Leidys Dominguez, Research Assistant (Sept. 22, 1999) (on
file with author); IDAHO DEPARTWENT OF HEALTH AND WELFARE, WHAT is
MEDICAID? 14 (1999) (stating that Medicaid will not cover prescription drugs unless
considered to be medically necessary); cf. Idaho May Violate Federal Law For De-
nying Impotence Drug, supra note 37, at 5b.
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Indiana Excluded from coverage'6
Iowa Maximum of 4 doses per
month
I67
Kansas Maximum of 10 tablets per
month6 s
Kentucky Maximum of 4 tablets per month
with prior authorization
69
Louisiana Maximum of 6 tablets per
month
170
Maine Maximum of 6 tablets with I
prescription per month'
7
'
Maryland Maximum of 6 tablets per month
with a maximum of 2 refills
172
Massachusetts Prior authorization required; gen-
erally limited to 4 tablets per
month. 173
165 See E-mail from Marvin Hazelwood, Pharmacy Benefits Manager, Illinois
Med. Assistance Program, to Leidys Dominguez, Research Assistant (Sept. 15, 1999)
(on file with author).
16 Prior to terminating coverage, Indiana paid for Viagra for 140 men with a
total cost of $11,400 out of a total Medicaid prescription drug budget of $2.5 billion.
See Indiana: Medicaid Program Won't Cover Viagra, AM. HEALTH LINE, June 26,
1998; see also Gelarden, supra note 116, at Cl. The Indiana Medicaid Agency did
not respond to the Fall 1999 survey of state Medicaid agencies.
167 See E-mail from R. Joe Mahrenholz to Leidys Dominguez, Research As-
sistant (Oct. 4, 1999) (on file with author).
168 See E-mail from Karen Braman, Pharmacy Program Manager, Kansas
Adult & Med. Serv. Comm'n, to Leidys Dominguez, Research Assistant, (Sept. 16,
1999) (on file with author).
169 See E-mail from Debra Bahr to Leidys Dominguez, Research Assistant
(Sept. 28, 1999) (on file with author). Kentucky requires the physician to submit
information on the age of the patient, the patient's history (especially cardiovascular),
a complete physical examination to rule out penile deformation, angulation or Peyro-
nie's disease, a review of current mediations, a statement that the patient has erectile
dysfunction, and whether the patient is a smoker. See id.
170See Hendren, supra note 114, at A3. Louisiana did not respond to the Fall
1999 survey of state Medicaid agencies. However, as of 1998, Viagra was covered
under the Louisiana Medicaid program. See 1998 LA. SESs. LAw. SERv. Hs. CONC.
REs. 48 (West) (limiting Medicaid coverage of sildenafil citrate).
171 Telephone conversation between Grace Mora, Research Assistant, and
Donna D, Clerk 3 at the Medicaid Office (Feb. 8, 2000).
172 See Managed Care Organization Transmittal No. 6 from Joseph M. Mill-
stone, Director, Med. Care Policy Admin., Maryland Med. Assistance Program (Aug.
21, 1998) (on file with author).
173 See E-mail from Christopher Burke, Pharmacy Program Analyst, Mass.
Div. of Med. Assistance, to Leidys Dominguez, Research Assistant (Sept. 16, 1999)
(on file with author). In the fiscal year ended June 30, 1999, the total costs attribut-
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Michigan Excluded from coverage
1 74
Minnesota Prior authorization required;
maximum of 6 tablets per
month' 75
Mississippi Maximum of 4 tablets per month
with prior authorization'
76
Missouri Prior authorization required;
maximum of 8 tablets per
month1
77
Montana Prior authorization required;
maximum of 7 tablets per
month' 73
Nebraska Prior authorization required;
maximum of 6 tablets per
month1
79
Nevada Covered without limitation"'
able to coverage of Viagra were $2,207 based on a total of 46 prescriptions filled. See
id. See also E-mail from Gary Gilmore, Pharmacist, Massachusetts Div. of Med.
Assistance, to Leidys Dominguez, Research Assistant (Sept. 17, 1999) (on file with
author) (describing criteria required before Massachusetts Medicaid will cover
Viagra).
'74 See State Resisting Pressure to Pay for Viagra Treatments, GRAND RAPIDS
PRESS, Sept. 12, 1998, at A12 (reporting why Michigan refuses Medicaid coverage of
Viagra); Michigan: Ready to Fight Viagra Medicaid Mandate, AzMi. HEALTH LINE,
May 29, 1998. Michigan did not respond to the Fall 1999 survey of state Medicaid
agencies.
175 See E-mail from Cody C. Wiberg, Acting Pharmacy Program Manager,
Minnesota Dep't of Hum. Serv., to Leidys Dominguez, Research Assistant (Sept. 15,
1999) (on file with author); Minnesota Dep't of Hum. Serv., News Release, State to
Provide Provisional Coverage of Viagra Under Medical Assistance (Medicaid) Pro-
grain (Sept. 9, 1998) (on file with author); see also Maura Lemer, Minnesota Will
Pay for Viagra Through Medicaid Program, STAR-TRIB. (Minneapolis), Sept. 10,
1998, at 3B; Maura Lemer, Restrictions on Medicaid Coverage of Viagra Urged,
STR Tm. (Minneapolis), Aug. 8, 1998, at B3.
176 Telephone conversation between Grace Mora, Research Assistant, and
Johnnie Price, Medicaid Auditor, Pharmacy Div., Medicaid Program (Feb. 8, 2000).
177 See E-mail from Victomine@aol.com to Leidys Dominguez, Research
Assistant (Sept. 15, 1999) (on file with author).
17, See E-mail from Dorothy Poulsen, Montana Dep't of Pub. Health & Serv.,
Medicaid Serv. Bureau, to Leidys Dominguez, Research Assistant (Sept. 17, 1999)
(on file with author).
179 See Ric Compton & Gary Cheloha, Nebraska Health & Hum. Serv. Sys.,
Provider Bulletin: Pharmacological Treatment of Sexual Dysfunction: Prior Authori-
zation Requirements (Dec. 18, 1998) (on file with author).
', See Letter from April Townley, Deputy Administrator, Nevada Div. of
Health Care Financing Policy to Medicaid Providers (Aug. 3, 1998) (on file with
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New Hampshire Excluded from coverage 8'
New Jersey Maximum of 4 tablets per
month1
82
New Mexico Maximum of 4 tablets per
month
8 3
New York Maximum of 6 tablets per
month 184
North Carolina Maximum of 2 tablets per
month'8
North Dakota Covered without limitation8 6
Ohio Excluded from coverage8
Oklahoma Excluded from coverage 8"
Oregon Excluded from coverage' 9
author). As noted in the letter, no limitations or prior authorization requirements were
established because "the prescription rate of Viagra for Medicaid clients is low." Id.
181 See NEw HAMPSHIRE DEP'T OF HEALTH & HUM. SERV., MEDICAID
SERvicEs (Mar. 1998) (stating that coverage of Viagra is excluded as a "medication
... for the purpose of contributing to or enhancing fertility or procreation") (on file
with author).
182 See E-mail from Edward J. Vaccaro, Assistant Director, New Jersey Div.
of Med. Assistance & Health Serv., Office of Health Serv. Admin., to Leidys Dom-
inguez, Research Assistant (Oct. 20, 1999) (on file with author).
183 See Telephone message by New Mexico Medicaid Agency representative
on answering machine of Leidys Dominguez, Research Assistant (Oct. 5, 1999)
(copy of transcription of message on file with author).
184 See New York Dep't of Health, supra note 102.
185 See North Carolina Div. of Med. Assistance, Drug Coverage for Impotence
Drugs (effective Mar. 1, 1999) (on file with author). Prior authorization is required
for males 44 years old and younger. See id.
'
86 See E-mail from Rick Detwiller, Administrator, Pharmacy Serv., to Leidys
Dominguez, Research Assistant (Oct. 4, 1999) (on file with author). Mr. Detwiller's
message also emphasized that, "[u]tilization reports suggest that Viagra usage re-
mains low. Id.
187 See E-mail from Robyn Colby, Medicaid Policy Chief, Office of Medicaid,
Ohio Dep't of Hum. Serv., to Leidys Dominguez, Research Assistant (Sept. 29, 1999)
(on file with author). However, coverage of Viagra is "still under consideration." Id.
188 Oklahoma is still evaluating coverage. Telephone conversation between
Grace Mora, Research Assistant, and John Crumly, Pharmacy Director, Oklahoma
Health Care Authority (Feb. 7, 2000).
189 See E-mail from Beverly Castor, Oregon Dep't of Hum. Serv., Office of
Med. Assistance Programs, to Leidys Dominguez (Sept. 20, 1999) (on file with
author). Oregon is operating its Medicaid program under a waiver of several federal
Medicaid standards pursuant to section 1115 of the Social Security Act, 42 U.S.C.
§1315 (1994). See Sara Rosenbaum, Mothers and Children Last: The Oregon Medi-
caid Experiment, 18 Ai, . J.L. & MED. 97 (1992) (evaluating the design of the Medi-
caid program enacted by Oregon). See generally Note, The Oregon Health Care Pro-
posal and the Americans with Disabilities Act, 106 HARv. L. REv. 1296 (1993) (de-
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Pennsylvania Maximum of 4 tablets per month
with prior authorization
90
Rhode Island Prior authorization required;
maximum of 8 tablets per
month 91
South Carolina Prior authorization required;
maximum of 3 tablets per
month
9 2
South Dakota Excluded from coverage
9 3
Tennessee Undetermined1
9 4
scribing the Oregon Plan's interaction with the ADA); W. John Thomas, The Oregon
Medicaid Proposal: Ethical Paralysis, Tragic Democracy, and the Fate of a Utili-
tarian Health Care Program, 72 OR. L. REv. 47 (1993) (discussing the innovative
Medicaid program enacted by Oregon in 1989). Oregon has prioritized diagnoses or
conditions for which funding is available. Impotence falls below the funded line on
the prioritized health services list. See E-mail from Beverly Castor, supra. This ex-
clusion reflects a change in the number of diagnoses or conditions for which funding
was available in 1998. See Viagra Coverage: Oregon Says 'Yes,' But Not Alabama,
supra note 102 (describing coverage of patients whose impotence resulted from or-
ganic, rather than psychological causes). The exclusion became the subject of politi-
cal action by advocates for poor, disabled and older men. See Hopkins Koglin, supra
note 102, at Dl.
" Telephone conversation between Grace Mora, Research Assistant, and Joe
Concino, Pharmacy Supervisor, Bureau of Policy, Budget & Planning, Pharmacy
Serv. Section (Feb. 7,2000).
"91 See E-mail from Paula Avarista to Leidys Dominguez, Research Assistant
(Sept. 15, 1999) (on file with author).
192 See E-mail from James Assey to Leidys Dominguez, Research Assistant
(Sept. 16, 1999) (on file with author); Gwen Power, Director, South Carolina Dep't
of Health & Hum. Serv., Special Authorization (SA) Guidelines/Limitations for
Pharmaceuticals Indicated for Treatment of Erectile Dysfunction (ED), MEDICAID
BuLL. (Dec. 23, 1998) (on file with author).
19A Telephone conversation between Grace Mora, Research Assistant, and
Mark Peterson, Pharmacy Consultant, Dep't of Soc. Serv. (Feb. 7, 2000). However,
Viagra might be covered through prior authorization on a case-by-case basis. Id.
194 See E-mail from Leo Sullivan, TennCare Pharmacy Director, to Leidys
Dominguez, Research Assistant (Oct. 1, 1999) (on file with author). As stated by the
Tennessee representative, "all medically necessary drugs are covered by the
TennCare MCOs." Id. However, there is no indication that Viagra is considered to be
.medically necessary" under this program. See Mary Powers, When Viagra Isn't the
Answer; Although New Pill Grabs the Headlines, Other Impotence Treatments are
Available, COMM. APPEAL (Memphis, Tenn.), June 14, 1998, at Fl. The Tennessee
Medicaid program operates a section 1115 waiver program called TennCare through
which Medicaid beneficiaries are placed in a variety of MCOs (medical care organi-
zations). The scope of services and the availability of care vary significantly from
plan to plan. For a discussion of the TennCare program, see James F. Blumstein &
Frank A Sloan, Health Care Reform Through Medicaid Managed Care: Tennessee
(TennCare) as a Case Study and a Paradigm, 53 VAND. L. REv. 125 (2000). See
generally Gordon Bonnyman, Jr. & Michele M. Johnson, Unseen Peril: Inadequate
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Enrollee Grievance Protections in Public Managed Care Programs, 65 TENN. L.
REv. 359 (1998) (discussing grievance processes in managed care); Judith M. Rosen-
berg & David T. Zaring, Recent Developments, Managing Medicaid Waivers: Sec-
tion 1115 and State Health Care Reform, 32 HARv. J. ON LEGIS. 545 (1995) (dis-
cussing Medicaid waivers and state reform).
195 See E-mail from Curtis Burch to Leidys Dominguez, Research Assistant
(Sept. 17, 1999) (on file with author).
196 See E-mail from Duane Parke, Utah Medicaid Agency, to Leidys Domin-
guez, Research Assistant (Sept. 30, 1999) (on file with author). Apparently this
maximum represented a reduction by one-half in the coverage previously available.
See Yep, Florida's One of 10 States Giving Viagra to Impotent Poor, supra note 114
(describing a limit of 10 pills per month based on the "normal patterns of men").
197 See E-mail from Samantha Haley to Leidys Dominguez, Research Assis-
tant (Oct. 20, 1999) (on file with author).
'
9 See Viagra: Virginia Says No, States Fear Federal Mandate, AM. HEALTH
LINE (May 13, 1998) (reporting on exclusion of Viagra from Medicaid coverage).
Virginia did not respond to the Fall 1999 survey of state Medicaid agencies.
199 See E-mail from Sift Childs, Pharmacy Research Specialist, Washington
Dep't of Soc. & Health Serv. to Leidys Dominguez, Research Assistant (Sept. 20,
1999) (on file with author).
200 See E-mail from Peggy King to Leidys Dominguez, Research Assistant
(Sept. 15, 1999) (on file with author).
201 See E-mail from Richard Carr to Leidys Dominguez, Research Assistant
(Sept. 22, 1999) (on file with author).
202 Telephone conversation between Grace Mora, Research Assistant, and
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Texas Maximum of 6 tablets per
month' 95
Utah Maximum of 5 tablets per
month' 96
Vermont Prior authorization required;
maximum of 4 tablets per
month' 97
Virginia Excluded from coverage'9"
Washington Covered on a pre-authorization
(case-by-case) basis' 99
West Virginia Prior authorization required;
maximum of 6 tablets per
month200
Wisconsin Excluded from coverage20'
Wyoming Maximum of 6 tablets per
month202
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APPENDIX B: SECTION 1927 OF THE SOCIAL
SECURITY ACT
§ 1396r-8. Payment for covered outpatient drugs
(a) Requirement for rebate agreement.
(1) In general. In order for payment to be available under section
1396b(a) [section 1903(a)] for covered outpatient drugs of a manu-
facturer, the manufacturer must have entered into and have in effect
a rebate agreement described in subsection (b) with the Secretary,
on behalf of States (except that, the Secretary may authorize a State
to enter directly into agreements with a manufacturer), and must
meet the requirements of paragraph (5) (with respect to drugs pur-
chased by a covered entity on or after the first day of the first month
that begins after November 4, 1992 [the date of the enactment of ti-
tle VI of the Veterans Health Care Act of 1992]) and paragraph (6).
Any agreement between a State and a manufacturer prior to April 1,
1991, shall be deemed to have been entered into on January 1, 1991,
and payment to such manufacturer shall be retroactively calculated
as if the agreement between the manufacturer and the State had been
entered into on January 1, 1991. If a manufacturer has not entered
into such an agreement before March 1, 1991, such an agreement,
subsequently entered into, shall become effective as of the date on
which the agreement is entered into or, at State option, on any date
thereafter on or before the first day of the calendar quarter that be-
gins more than 60 days after the date the agreement is entered into.
(2) Effective date. Paragraph (1) shall first apply to drugs dis-
pensed under this subchapter on or after January 1, 1991.
(3) Authorizing payment for drugs not covered under rebate
agreements. Paragraph (1), and section 1396b(i)(10)(A) [section
1903(i)(10)(A)] of this title, shall not apply to the dispensing of a
single source drug or innovator multiple source drug if (A)(i) the
State has made a determination that the availability of the drug is
essential to the health of beneficiaries under the State plan for
medical assistance; (ii) such drug has been given a rating of 1-A by
the Food and Drug Administration; and (iii)(I) the physician has
obtained approval for use of the drug in advance of its dispensing in
accordance with a prior authorization program described in subsec-
tion (d), or (II) the Secretary has reviewed and approved the State's
determination under subparagraph (A); or (B) the Secretary deter-
mines that in the first calendar quarter of 1991, there were extenu-
ating circumstances.
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(4) Effect on existing agreements. In the case of a rebate agree-
ment in effect between a State and a manufacturer on November 5,
1990 [the date of the enactment of this section], such agreement, for
the initial agreement period specified therein, shall be considered to
be a rebate agreement in compliance with this section with respect
to that State, if the State agrees to report to the Secretary any re-
bates paid pursuant to the agreement and such agreement provides
for a minimum aggregate rebate of 10 percent of the State's total
expenditures under the State plan for coverage of the manufacturer's
drugs under this subchapter. If, after the initial agreement period,
the State establishes to the satisfaction of the Secretary that an
agreement in effect on November 5, 1990, provides for rebates that
are at least as large as the rebates otherwise required under this sec-
tion, and the State agrees to report any rebates under the agreement
to the Secretary, the agreement shall be considered to be a rebate
agreement in compliance with the section for the renewal periods of
such agreement.
(5) Limitation on prices of drugs purchased by covered entities.
(A) Agreement with Secretary. A manufacturer meets the re-
quirements of this paragraph if the manufacturer has entered
into an agreement with the Secretary that meets the require-
ments of section 256b [section 340B of the Public Health
Service Act] of this title with respect to covered outpatient
drugs purchased by a covered entity on or after the first day of
the first month that begins after November 4, 1992 [the date of
the enactment of this paragraph].
(B) Covered entity defined. In this subsection, the term "cov-
ered entity" means an entity described in section 256b(a)(4)
[section 340B(a)(4) of the Public Health Service Act] of this
title.
(C) Establishment of alternative mechanism to ensure
against duplicate discounts or rebates. If the Secretary does
not establish a mechanism under section 256b(a)(5)(A) [sec-
tion 340B(a)(5)(A) of the Public Health Service Act] within 12
months of November 4, 1992, the following requirements shall
apply:
(i) Entities. Each covered entity shall inform the single
State agency under section 1396a(a)(5) [section
1902(a)(5)] when it is seeking reimbursement from the
State plan for medical assistance described in section
1396d(a)(12) [section 1905(a)(12)] with respect to a unit
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of any covered outpatient drug which is subject to an
agreement under section 256b(a) [340B(a)] of this title.
(ii) State agency. Each such single State agency shall
provide a means by which a covered entity shall indicate
on any drug reimbursement claims form (or format, where
electronic claims management is used) that a unit of the
drug that is the subject of the form is subject to an agree-
ment under section 256b [section 340B] of this title, and
not submit to any manufacturer a claim for a rebate pay-
ment under subsection (b) with respect to such a drug.
(D) Effect of subsequent amendments. In determining
whether an agreement under subparagraph (A) meets the re-
quirements of section 256b [340B of the Public Health Service
Act] of this title, the Secretary shall not take into account any
amendments to such section that are enacted after November 4,
1992 [the enactment of title VI of the Veterans Health Care
Act of 1992].
(E) Determination of compliance. A manufacturer is deemed
to meet the requirements of this paragraph if the manufacturer
establishes to the satisfaction of the Secretary that the manu-
facturer would comply (and has offered to comply) with the
provisions of section 256b [section 340B of the Public Health
Service Act] (as in effect immediately after November 4, 1992)
and would have entered into an agreement under such section
(as such section was in effect at such time), but for a legisla-
tive change in such section after November 4, 1992.
(6) Requirements relating to master agreements for drugs pro-
cured by Department of Veterans Affairs and certain other Fed-
eral agencies.
(A) In general. A manufacturer meets the requirements of this
paragraph if the manufacturer complies with the provisions of
section 8126 of Title 38 [United States Code], including the
requirement of entering into a master agreement with the Sec-
retary of Veterans Affairs under such section.
(B) Effect of subsequent amendments. In determining
whether a master agreement described in subparagraph (A)
meets the requirements of section 8126 of Title 38 [United
States Code], the Secretary shall not take into account any
amendments to such section that are enacted after November 4,
1992 [the enactment of title VI of the Veterans Health Care
Act of 1992].
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(C) Determination of compliance. A manufacturer is deemed
to meet the requirements of this paragraph if the manufacturer
establishes to the satisfaction of the Secretary that the manu-
facturer would comply (and has offered to comply) with the
provisions of section 8126 of Title 38 [United States Code], (as
in effect immediately after November 4, 1992) and would have
entered into an agreement under such section (as such section
was in effect at such time), but for a legislative change in such
section after November 4, 1992.
(b) Terms of rebate agreement.
(1) Periodic rebates.
(A) In general. A rebate agreement under this subsection shall
require the manufacturer to provide, to each State plan ap-
proved under this subchapter, a rebate for a rebate period in an
amount specified in subsection (c) for covered outpatient drugs
of the manufacturer dispensed after December 31, 1990, for
which payment was made under the State plan for such period.
Such rebate shall be paid by the manufacturer not later than 30
days after the date of receipt of the information described in
paragraph (2) for the period involved.
(B) Offset against medical assistance. Amounts received by a
State under this section (or under an agreement authorized by
the Secretary under subsection (a)(1) or an agreement de-
scribed in subsection (a)(4) of this section) in any quarter shall
be considered to be a reduction in the amount expended under
the State plan in the quarter for medical assistance for purposes
of section 1396b(a)(1) [section 1903(a)(1)] of this title.
(2) State provision of information.
(A) State responsibility. Each State agency under subchapter
shall report to each manufacturer not later than 60 days after
the end of each rebate period and in a form consistent with a
standard reporting format established by the Secretary, infor-
mation on the total number of units of each dosage form and
strength and package size of each covered outpatient drug dis-
pensed after December 31, 1990, for which payment was made
under the plan during the period, and shall promptly transmit a
copy of such report to the Secretary.
(B) Audits. A manufacturer may audit the information pro-
vided (or required to be provided) under subparagraph (A).
Adjustments to rebates shall be made to the extent that infor-
242 (Vol. I I:I89
MEDICAID AND VIAGRA
mation indicates that utilization was greater or less than the
amount previously specified.
(3) Manufacturer provision of price information.
(A) In general. Each manufacturer with an agreement in effect
under this section shall report to the Secretary-
(i) not later than 30 days after the last day of each rebate
period under the agreement (beginning on or after January
1, 1991), on the average manufacturer price (as defined in
subsection (k)(1) of this section) and, (for single source
drugs and innovator multiple source drugs), the manu-
facturer's best price (as defined in subsection (c)(2)(B) of
this section) for covered outpatient drugs for the rebate
period under the agreement, and
(ii) not later than 30 days after the date of entering into an
agreement under this section on the average manufacturer
price (as defined in subsection (k)(1) of this section) as of
October 1, 1990[,] for each of the manufacturer's covered
outpatient drugs.
(B) Verification surveys of average manufacturer price.
The Secretary may survey wholesalers and manufacturers that
directly distribute their covered outpatient drugs, when neces-
sary, to verify manufacturer prices reported under subpara-
graph (A). The Secretary may impose a civil monetary penalty
in an amount not to exceed $100,000 on a wholesaler, manu-
facturer, or direct seller, if the wholesaler, manufacturer, or di-
rect seller of a covered outpatient drug refuses a request for in-
formation about charges or prices by the Secretary in connec-
tion with a survey under this subparagraph or knowingly pro-
vides false information. The provisions of section 1320a-7a(a)
[section 1128A(a)] of this title (other than subsections (a)
(with respect to amounts of penalties or additional assess-
ments) and (b)) shall apply to a civil money penalty under this
subparagraph in the same manner as such provisions apply to a
penalty or proceeding under section 1320a-7a(a) [section
1 128A(a)] of this title.
(C) Penalties.
(i) Failure to provide timely information. In the case of
a manufacturer with an agreement under this section that
fails to provide information required under subparagraph
(A) on a timely basis, the amount of the penalty shall be
increased by $10,000 for each day in which such infor-
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mation has not been provided and such amount shall be
paid to the Treasury, and, if such information is not re-
ported within 90 days of the deadline imposed, the
agreement shall be suspended for services furnished after
the end of the 90-day period and until the date such in-
formation is reported (but in no case shall such suspen-
sion be for a period of less than 30 days).
(ii) False information. Any manufacturer with an agree-
ment under this section that knowingly provides false in-
formation is subject to a civil money penalty in an amount
not to exceed $100,000 for each item of false information.
Such civil money penalties are in addition to other penal-
ties as may be prescribed by law. The provisions of sec-
tion 1320a-7a [section 1128A] (other than subsections (a)
and (b)) shall apply to a civil money penalty under this
subparagraph in the same manner as such provisions ap-
ply to a penalty or proceeding under section 1320a-7a(a)
[section 1128A(a)] of this title.
(D) Confidentiality of information. Notwithstanding any
other provision of law, information disclosed by manufacturers
or wholesalers under this paragraph or under an agreement
with the Secretary of Veterans Affairs described in subsection
(a)(6)(A)(ii) of this section is confidential and shall not be dis-
closed by the Secretary or the Secretary of Veterans Affairs or
a State agency (or contractor therewith) in a form which dis-
closes the identity of a specific manufacturer or wholesaler,
prices charged for drugs by such manufacturer or wholesaler,
except-
(i) as the Secretary determines to be necessary to carry
out this section,
(ii) to permit the Comptroller General to review the in-
formation provided, and
(iii) to permit the Director of the Congressional Budget
Office to review the information provided.
(4) Length of agreement.
(A) In general. A rebate agreement shall be effective for an
initial period of not less than 1 year and shall be automatically
renewed for a period of not less than one year unless termi-
nated under subparagraph (B).
(B) Termination.
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(i) By the Secretary. The Secretary may provide for ter-
mination of a rebate agreement for violation of the re-
quirements of the agreement or other good cause shown.
Such termination shall not be effective earlier than 60
days after the date of notice of such termination. The Sec-
retary shall provide, upon request, a manufacturer with a
hearing concerning such a termination, but such hearing
shall not delay the effective date of the termination.
(ii) By a manufacturer. A manufacturer may terminate a
rebate agreement under this section for any reason. Any
such termination shall not be effective until the calendar
quarter beginning at least 60 days after the date the manu-
facturer provides notice to the Secretary.
(iii) Effectiveness of termination. Any termination under
this subparagraph shall not affect rebates due under the
agreement before the effective date of its termination.
(iv) Notice to States. In the case of a termination under
this subparagraph, the Secretary shall provide notice of
such termination to the States within not less than 30 days
before the effective date of such termination.
(v) Application to terminations of other agreements.
The provisions of this subparagraph shall apply to the
terminations of agreements described in section256b(a)(1)
[section 340B(a)(1) of the Public Health Service Act] of
this title and master agreements described in section
8126(a) of Title 38 [United States Code].
(C) Delay before reentry. In the case of any rebate agreement
with a manufacturer under this section which is terminated,
another such agreement with the manufacturer (or a successor
manufacturer) may not be entered into until a period of 1 cal-
endar quarter has elapsed since the date of the termination,
unless the Secretary finds good cause for an earlier reinstate-
ment of such an agreement.
(c) Determination of amount of rebate.
(1) Basic rebate for single source drugs and innovator multiple
source drugs.
(A) In general. Except as provided in paragraph (2), the
amount of the rebate specified in this subsection for a rebate
period (as defined in subsection (k)(8)of this section) with re-
spect to each dosage form and strength of a single source drug
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or an innovator multiple source drug shall be equal to the
product of-
(i) the total number of units of each dosage form and
strength paid for under the State plan in the rebate period
(as reported by the State); and
(ii) subject to subparagraph (B)(ii), the greater of-
(I) the difference between the average manufacturer price
and the best price (as defined in subparagraph (C)) for the
dosage form and strength of the drug, or (H) the mini-
mum rebate percentage (specified in subparagraph (B)(i))
of such average manufacturer price, for the rebate period.
(B) Range of rebates required.
(i) Minimum rebate percentage. For purposes of sub-
paragraph (A)(ii)(II), the "minimum rebate percentage"
for rebate periods beginning- (I) after December 31,
1990, and before October 1, 1992, is 12.5 percent;
(II) after September 30, 1992, and before January 1,
1994, is 15.7 percent; (HI) after December 31, 1993, and
before January 1, 1995, is 15.4 percent; (IV) after De-
cember 31, 1994, and before January 1, 1996, is 15.2 per-
cent; and (V) after December 31, 1995, is 15.1 percent.
(ii) Temporary limitation on maximum rebate amount.
In no case shall the amount applied under subparagraph
(A)(ii) for a rebate period beginning- (I) before January
1, 1992, exceed 25 percent of the average manufacturer
price; or (II) after December 31, 1991, and before Janu-
ary 1, 1993, exceed 50 percent of the average manufac-
turer price.
(C) Best price defined. For purposes of this section-
(i) In general. The term "best price" means, with respect
to a single source drug or innovator multiple source drug
of a manufacturer, the lowest price available from the
manufacturer during the rebate period to any wholesaler,
retailer, provider, health maintenance organization, non-
profit entity, or governmental entity within the United
States, excluding- (1) any prices charged on or after
October 1, 1992, to the Indian Health Service, the De-
partment of Veterans Affairs, a State home receiving
funds under section 1741 of Title 38 [United States
Code], the Department of Defense, the Public Health
Service, or a covered entity described in subsection
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(a)(5)(B) of this section; (I1) any prices charged under the
Federal Supply Schedule of the General Services Admini-
stration; (11) any prices used under a State pharmaceuti-
cal assistance program; and (IV) any depot prices and
single award contract prices, as defined by the Secretary,
of any agency of the Federal Government.
(ii) Special rules. The term "best price"-- (l) shall be in-
clusive of cash discounts, free goods that are contingent
on any purchase requirement, volume discounts, and re-
bates (other than rebates under this section); (I shall be
determined without regard to special packaging, labeling,
or identifiers on the dosage form or product or package;
and (EIl) shall not take into account prices that are merely
nominal in amount.
(2) Additional rebate for single source and innovator multiple
source drugs.
(A) In general. The amount of the rebate specified in this sub-
section for a rebate period, with respect to each dosage form
and strength of a single source drug or an innovator multiple
source drug, shall be increased by an amount equal to the
product of-
(i) the total number of units of such dosage form and
strength dispensed after December 31, 1990, for which
payment was made under the State plan for the rebate pe-
riod; and
(ii) the amount (if any) by which- (1) the average manu-
facturer price for the dosage form and strength of the drug
for the period, exceeds (II) the average manufacturer
price for such dosage form and strength for the calendar
quarter beginning July 1, 1990 (without regard to whether
or not the drug has been sold or transferred to an entity,
including a division or subsidiary of the manufacturer,
after the first day of such quarter), increased by the per-
centage by which the consumer price index for all urban
consumers (United States city average) for the month be-
fore the month in which the rebate period begins exceeds
such index for September 1990.
(B) Treatment of subsequently approved drugs. In the case
of a covered outpatient drug approved by the Food and Drug
Administration after October 1, 1990, clause (ii)(II) of sub-
paragraph (A) shall be applied by substituting "the first full
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calendar quarter after the day on which the drug was first mar-
keted" for 'the calendar quarter beginning July 1, 1990" and
"the month prior to the first month of the first full calendar
quarter after the day on which the drug was first marketed" for
"September 1990".
(3) Rebate for other drugs.
(A) In general. The amount of the rebate paid to a State for a
rebate period with respect to each dosage form and strength of
covered outpatient drugs (other than single source drugs and
innovator multiple source drugs) shall be equal to the product
of-
(i) the applicable percentage (as described in subpara-
graph (B)) of the average manufacturer price for the dos-
age form and strength for the rebate period, and
(ii) the total number of units of such dosage form and
strength dispensed after December 31, 1990, for which
payment was made under the State plan for the rebate pe-
riod.
(B) Applicable percentage defined. For purposes of subpara-
graph (A)(i), the "applicable percentage" for rebate periods
beginning-
(i) before January 1, 1994, is 10 percent, and
(ii) after December 31, 1993, is 11 percent.
(d) Limitations on coverage of drugs.
(1) Permissible restrictions.
(A) A State may subject to prior authorization any covered
outpatient drug. Any such prior authorization program shall
comply with the requirements of paragraph (5).
(B) A State may exclude or otherwise restrict coverage of a
covered outpatient drug if-
(i) the prescribed use is not for a medically accepted indi-
cation (as defined in subsection (k)(6) of this section);
(ii) the drug is contained in the list referred to in para-
graph (2);
(iii) the drug is subject to such restrictions pursuant to an
agreement between a manufacturer and a State authorized
by the Secretary under subsection (a)(1) of this section or
in effect pursuant to subsection (a)(4) of this section; or
(iv) the State has excluded coverage of the drug from its
formulary established in accordance with paragraph (4).
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(2) List of drugs subject to restriction. The following drugs or
classes of drugs, or their medical uses, may be excluded from cov-
erage or otherwise restricted:
(A) Agents when used for anorexia, weight loss, or weight
gain.
(B) Agents when used to promote fertility.
(C) Agents when used for cosmetic purposes or hair growth.
(D) Agents when used for the symptomatic relief of cough and
colds.
(E) Agents when used to promote smoking cessation.
(F) Prescription vitamins and mineral products, except prenatal
vitamins and fluoride preparations.
(G) Nonprescription drugs.
(H) Covered outpatient drugs which the manufacturer seeks to
require as a condition of sale that associated tests or monitor-
ing services be purchased exclusively from the manufacturer or
its designee.
(I) Barbiturates.
(J) Benzodiazepines.
(3) Update of drug listings. The Secretary shall, by regulation, pe-
riodically update the list of drugs or classes of drugs described in
paragraph (2) or their medical uses, which the Secretary has deter-
mined, based on data collected by surveillance and utilization re-
view programs of State medical assistance programs, to be subject
to clinical abuse or inappropriate use.
(4) Requirements for formularies. A State may establish a for-
mulary if the formulary meets the following requirements:
(A) The formulary is developed by a committee consisting of
physicians, pharmacists, and other appropriate individuals ap-
pointed by the Governor of the State (or, at the option of the
State, the State's drug use review board established under sub-
section (g)(3) of this section).
(B) Except as provided in subparagraph (C), the formulary in-
cludes the covered outpatient drugs of any manufacturer which
has entered into and complies with an agreement under sub-
section (a) of this section (other than any drug excluded from
coverage or otherwise restricted under paragraph (2)).
(C) A covered outpatient drug may be excluded with respect to
the treatment of a specific disease or condition for an identi-
fied population (if any) only if, based on the drug's labeling
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(or, in the case of a drug the prescribed use of which is not ap-
proved under the Federal Food, Drug, and Cosmetic Act [21
U.S.C.A. §§ 301 et seq.] but is a medically accepted indica-
tion, based on information from the appropriate compendia de-
scribed in subsection (k)(6) of this section), the excluded drug
does not have a significant, clinically meaningful therapeutic
advantage in terms of safety, effectiveness, or clinical outcome
of such treatment for such population over other drugs in-
cluded in the formulary and there is a written explanation
(available to the public) of the basis for the exclusion.
(D) The State plan permits coverage of a drug excluded from
the formulary (other than any drug excluded from coverage or
otherwise restricted under paragraph (2)) pursuant to a prior
authorization program that is consistent with paragraph (5).
(E) The formulary meets such other requirements as the Sec-
retary may impose in order to achieve program savings con-
sistent with protecting the health of program beneficiaries.
A prior authorization program established by a State under para-
graph (5) is not a formulary subject to the requirements of this para-
graph.
(5) Requirements of prior authorization programs. A State plan
under this subchapter may require, as a condition of coverage or
payment for a covered outpatient drug for which Federal financial
participation is available in accordance with this section, with re-
spect to drugs dispensed on or after July 1, 1991, the approval of the
drug before its dispensing for any medically accepted indication (as
defined in subsection (k)(6) of this section) only if the system pro-
viding for such approval-
(A) provides response by telephone or other telecommunica-
tion device within 24 hours of a request for prior authorization;
and
(B) except with respect to the drugs on the list referred to in
paragraph (2), provides for the dispensing of at least 72-hour
supply of a covered outpatient prescription drug in an emer-
gency situation (as defined by the Secretary).
(6) Other permissible restrictions. A State may impose limita-
tions, with respect to all such drugs in a therapeutic class, on the
minimum or maximum quantities per prescription or on the number
of refills, if such limitations are necessary to discourage waste, and
may address instances of fraud or abuse by individuals in any man-
ner authorized under this chapter.
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(e) Treatment of pharmacy reimbursement limits.
(1) In general. During the period beginning on January 1, 1991, and
ending on December 31, 1994-
(A) a State may not reduce the payment limits established by
regulation under this title or any limitation described in para-
graph (3) with respect to the ingredient cost of a covered out-
patient drug or the dispensing fee for such a drug below the
limits in effect as of January 1, 1991, and
(B) except as provided in paragraph (2), the Secretary may not
modify by regulation the formula established under sections
447.331 through 447.334 of title 42, Code of Federal Regula-
tions, in effect on November 5, 1990, to reduce the limits de-
scribed in subparagraph (A).
(2) Special rule. If a State is not in compliance with the regulations
described in paragraph (1)(B), paragraph (1)(A) shall not apply to
such State until such State is in compliance with such regulations.
(3) Effect on State maximum allowable cost limitations. This
section shall not supersede or affect provisions in effect prior to
January 1, 1991, or after December 31, 1994, relating to any maxi-
mum allowable cost limitation established by a State for payment by
the State for covered outpatient drugs, and rebates shall be made
under this section without regard to whether or not payment by the
State for such drugs is subject to such a limitation or the amount of
such a limitation.
[(4) Establishment of upper payment limits. HCFA shall estab-
lish a Federal upper reimbursement limit for each multiple source
drug for which the FDA has rated three or more products therapeu-
tically and additional formulations are rated as such and shall use
only such formulations when determining any such upper limit.
(g) Drug use review.
(1) In general.
(A) In order to meet the requirement of section
1396b(i)(10)(B) [section 1903(i)(10)(B)] of this title, a State
shall provide, by not later than January 1, 1993, for a drug use
review program described in paragraph (2) for covered outpa-
tient drugs in order to assure that prescriptions (i) are appro-
priate, (ii) are medically necessary, and (iii) are not likely to
result in adverse medical results. The program shall be de-
signed to educate physicians and pharmacists to identify and
reduce the frequency of patterns of fraud, abuse, gross overuse,
or inappropriate or medically unnecessary care, among physi-
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cians, pharmacists, and patients, or associated with specific
drugs or groups of drugs, as well as potential and actual severe
adverse reactions to drugs including education on therapeutic
appropriateness, overutilization and underutilization, appropri-
ate use of generic products, therapeutic duplication, drug-
disease contraindications, drug-drug interactions, incorrect
drug dosage or duration of drug treatment, drug-allergy inter-
actions, and clinical abuse/misuse.
(B) The program shall assess date on drug use against prede-
termined standards, consistent with the following:
(i) compendia which shall consist of the following:
(I) American Hospital Formulary Service Drug Informa-
tion; (II) United States Pharmacopeia-Drug Information;
(Il) the DRUGDEX Information System; and
(IV) American Medical Association Drug Evaluations;
and
(ii) the peer-reviewed medical literature.
(C) The Secretary, under the procedures established in section
1396b [section 1903] of this title, shall pay to each State an
amount equal to 75 per centum of so much of the sums ex-
pended by the State plan during calendar years 1991 through
1993 as the Secretary determines is attributable to the state-
wide adoption of a drug use review program which conforms
to the requirements of this subsection.
(D) States shall not be required to perform additional drug use
reviews with respect to drugs dispensed to residents of nursing
facilities which are in compliance with the drug regimen re-
view procedures prescribed by the Secretary for such facilities
in regulations implementing section 1396r [section 1919], cur-
rently at section 483.60 of title 42, Code of Federal Regula-
tions.
(2) Description of program. Each drug use review program shall
meet the following requirements for covered outpatient drugs:
(A) Prospective drug review.
(i) The State plan shall provide for a review of drug ther-
apy before each prescription is filled or delivered to an
individual receiving benefits under this subchapter, typi-
cally at the point-of-sale or point of distribution. The re-
view shall include screening for potential drug therapy
problems due to therapeutic duplication, drug-disease
contraindications, drug-drug interactions (including seri-
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ous interactions with nonprescription or over-the-counter
drugs), incorrect drug dosage or duration of drug treat-
ment, drug-allergy interactions, and clinical abuse/misuse.
Each State shall use the compendia and literature referred
to in paragraph (1)(B) as its source of standards for such
review.
(ii) As part of the State's prospective drug use review
program under this subparagraph applicable State law
shall establish standards for counseling of individuals re-
ceiving benefits under this subchapter by pharmacists
which includes at least the following: (I) The pharmacist
must offer to discuss with each individual receiving bene-
fits under this subchapter or caregiver of such individual
(in person, whenever practicable, or through access to a
telephone service which is toll-free for long-distance
calls) who presents a prescription, matters which in the
exercise of the pharmacist's professional judgment (con-
sistent with State law respecting the provision of such in-
formation), the pharmacist deems significant including
the following:
(aa) The name and description of the medication.
(bb) The route, dosage form, dosage, route of ad-
ministration, and duration of drug therapy.
(cc) Special directions and precautions for prepara-
tion, administration and use by the patient.
(dd) Common severe side or adverse effects or in-
teractions and therapeutic contraindications that may
be encountered, including their avoidance, and the
action required if they occur.
(ee) Techniques for self-monitoring drug therapy.
(ff) Proper storage.
(gg) Prescription refill information.
(hh) Action to be taken in the event of a missed
dose.
(II) A reasonable effort must be made by the pharmacist
to obtain, record, and maintain at least the following in-
formation regarding individuals receiving benefits under
this subehapter:
(aa) Name, address, telephone number, date of birth
(or age) and gender.
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(bb) Individual history where significant, including
disease state or states, known allergies and drug re-
actions, and a comprehensive list of medications and
relevant devices.
(cc) Pharmacist comments relevant to the individ-
ual's drug therapy.
Nothing in this clause shall be construed as requiring a
pharmacist to provide consultation when an individual re-
ceiving benefits under this title [42 USCS §§ 1396 et
seq.] or caregiver of such individual refuses such consul-
tation.
(B) Retrospective drug use review. The program shall pro-
vide, through its mechanized drug claims processing and in-
formation retrieval systems (approved by the Secretary under
section 1396b(r) [section 1903(r)) of this title) or otherwise,
for the ongoing periodic examination of claims data and other
records in order to identify patterns of fraud, abuse, gross
overuse, or inappropriate or medically unnecessary care,
among physicians, pharmacists and individuals receiving bene-
fits under this subchapter, or associated with specific drugs or
groups of drugs.
(C) Application of standards. The program shall, on an on-
going basis, assess data on drug use against explicit predeter-
mined standards (using the compendia and literature referred to
in subsection (1)(B) as the source of standards for such as-
sessment) including but not limited to monitoring for thera-
peutic appropriateness, overutilization and underutilization,
appropriate use of generic products, therapeutic duplication,
drug-disease contraindications, drug-drug interactions, incor-
rect drug dosage or duration of drug treatment, and clinical
abuse/misuse and, as necessary, introduce remedial strategies,
in order to improve the quality of care and to conserve pro-
gram funds or personal expenditures.
(D) Educational program. The program shall, through its
State drug use review board established under paragraph (3),
either directly or through contracts with accredited health care
educational institutions, State medical societies or State phar-
macists associations/societies or other organizations as speci-
fied by the State, and using data provided by the State drug use
review board on common drug therapy problems, provide for
active and ongoing educational outreach programs (including
the activities described in paragraph (3)(C)(iii) of this subsec-
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tion) to educate practitioners on common drug therapy prob-
lems with the aim of improving prescribing or dispensing
practices.
(3) State drug use review board.
(A) Establishment. Each State shall provide for the establish-
ment of a drug use review board (hereinafter referred to as the
"DUR Board") either directly or through a contract with a pri-
vate organization.
(B) Membership. The membership of the DUR Board shall
include health care professionals who have recognized knowl-
edge and expertise in one or more of the following:
(i) The clinically appropriate prescribing of covered out-
patient drugs.
(ii) The clinically appropriate dispensing and monitoring
of covered outpatient drugs.
(iii) Drug use review, evaluation, and intervention.
(iv) Medical quality assurance.
The membership of the DUR Board shall be made up at least
1/3 but no more than 51 percent licensed and actively practic-
ing physicians and at least 1/3 * * * licensed and actively
practicing pharmacists.
(C) Activities. The activities of the DUR Board shall include
but not be limited to the following:
(i) Retrospective DUR as defined in section (2)(B).
(ii) Application of standards as defined in (2)(C).
(iii) Ongoing interventions for physicians and pharma-
cists, targeted toward therapy problems or individuals
identified in the course of retrospective drug use reviews
performed under this subsection. Intervention programs
shall include, in appropriate instances, at least:
(I) information dissemination sufficient to ensure the
ready availability to physicians and pharmacists in the
State of information concerning its duties, powers, and
basis for its standards; (11) written, oral, or electronic re-
minders containing patient-specific or drug-specific (or
both) information and suggested changes in prescribing or
dispensing practices, communicated in a manner designed
to ensure the privacy of patient-related information;
(DII) use of face-to-face discussions between health care
professionals who are experts in rational drug therapy and
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selected prescribers and pharmacists who have been tar-
geted for educational intervention, including discussion of
optimal prescribing, dispensing, or pharmacy care prac-
tices, and follow-up face-to-face discussions; and
(IV) intensified review or monitoring of selected pre-
scribers or dispensers.
The Board shall re-evaluate interventions after an appropriate
period of time to determine if the intervention improved the
quality of drug therapy, to evaluate the success of the inter-
ventions and make modifications as necessary.
(D) Annual report. Each State shall require the DUR Board to
prepare a report on an annual basis. The State shall submit a
report on an annual basis to the Secretary which shall include a
description of the activities of the Board, including the nature
and scope of the prospective and retrospective drug use review
programs, a summary of the interventions used, an assessment
of the impact of these educational interventions on quality of
care, and an estimate of the cost savings generated as a result
of such program. The Secretary shall utilize such report in
evaluating the effectiveness of each State's drug use review
program.
(h) Electronic claims management.
(1) In general. In accordance with chapter 35 of Title 44 [United
States Code] (relating to coordination of Federal information pol-
icy), the Secretary shall encourage each State agency to establish, as
its principal means of processing claims for covered outpatient
drugs under this subchapter, a point-of-sale electronic claims man-
agement system, for the purpose of performing on-line, real time
eligibility verifications, claims data capture, adjudication of claims,
and assisting pharmacists (and other authorized persons) in applying
for and receiving payment.
(2) Encouragement. In order to carry out paragraph (1)-
(A) for calendar quarters during fiscal years 1991 and 1992,
expenditures under the State plan attributable to development
of a system described in paragraph (1) shall receive Federal fi-
nancial participation under section 1396b(a)(3)(A)(i) [section
1903(a)(3)(A)(i)] of this title (at a matching rate of 90 percent)
if the State acquires, through applicable competitive procure-
ment process in the State, the most cost-effective telecommu-
nications network and automatic data processing services and
equipment; and
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(B) the Secretary may permit, in the procurement described in
subparagraph (A) in the application of part 433 of title 42,
Code of Federal Regulations, and parts 95, 205, and 307 of ti-
tle 45, Code of Federal Regulations, the substitution of the
State's request for proposal in competitive procurement for
advance planning and implementation documents otherwise
required.
(i) Annual report.
(1) In general. Not later than May 1 of each year the Secretary shall
transmit to the Committee on Finance of the Senate, the Committee
on Energy and Commerce of the House of Representatives, and the
Committees on Aging of the Senate and the House of Representa-
tives a report on the operation of this section in the preceding fiscal
year.
(2) Details. Each report shall include information on-
(A) ingredient costs paid under this subchapter for single
source drugs, multiple source drugs, and nonprescription cov-
ered outpatient drugs;
(B) the total value of rebates received and number of manu-
facturers providing such rebates;
(C) how the size of such rebates compare with the size or [of]
rebates offered to other purchasers of covered outpatient drugs;
(D) the effect of inflation on the value of rebates required un-
der this section;
(E) trends in prices paid under this subchapter for covered out-
patient drugs; and
(F) Federal and State administrative costs associated with
compliance with the provisions of this subchapter.
(j) Exemption of organized health care settings.
(1) Covered outpatient drugs dispensed by health maintenance or-
ganizations, including medicaid managed care organizations that
contract under section 1396b(m) [section 1903(m)] of this title, are
not subject to the requirements of this section.
(2) The State plan shall provide that a hospital (providing medical
assistance under such plan) that dispenses covered outpatient drugs
using drug formulary systems, and bills the plan no more than the
hospital's purchasing costs for covered outpatient drugs (as deter-
mined under the State plan) shall not be subject to the requirements
of this section.
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(3) Nothing in this subsection shall be construed as providing that
amounts for covered outpatient drugs paid by the institutions de-
scribed in this subsection should not be taken into account for pur-
poses of determining the best price as described in subsection (c) of
this section.
(k) Definitions. In this section-
(1) Average manufacturer price. The term "average manufacturer
price" means, with respect to a covered outpatient drug of a manu-
facturer for a rebate period, the average price paid to the manufac-
turer for the drug in the United States by wholesalers for drugs dis-
tributed to the retail pharmacy class of trade, after deducting cus-
tomary prompt pay discounts.
(2) Covered outpatient drug. Subject to the exceptions in para-
graph (3), the term "covered outpatient drug" means-
(A) of those drugs which are treated as prescribed drugs for
purposes of section 1396d(a)(12) [section 1905(a)( 12)] of this
title, a drug which may be dispensed only upon prescription
(except as provided in paragraph (5)), and-
(i) which is approved for safety and effectiveness as a
prescription drug under section 505 or 507 of the Federal
Food, Drug, and Cosmetic Act [21 U.S.C.A. § 355 or
357] or which is approved under section 505j) of such
Act [21 U.S.C.A. § 3550)];
(ii) (I) which was commercially used or sold in the United
States before October 10, 1962 [the date of the enactment
of the Drug Amendments of 1962] or which is identical,
similar, or related (within the meaning of section
310.6(b)(1) of title 21 of the Code of Federal Regulations)
to such a drug, and (II) which has not been the subject of
a final determination by the Secretary that it is a "new
drug" (within the meaning of section 201(p) of the Fed-
eral Food, Drug, and Cosmetic Act [21 U.S.C.A. §
321(p)]) or an action brought by the Secretary under sec-
tion 301, 302(a), or 304(a) of such Act [21 U.S.C.A. §
331, 332(a), or 334(a)] to enforce section 502(f) or 505(a)
of such Act [21 U.S.C.A. § 352(0 or 355(a)]; or
(iii) (I) which is described in section 107(c)(3) of the
Drug Amendments of 1962 and for which the Secretary
has determined there is a compelling justification for its
medical need, or is identical, similar, or related (within
the meaning of section 310.6(b)(1) of title 21 of the Code
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of Federal Regulations) to such a drug, and (II) for which
the Secretary has not issued a notice of an opportunity for
a hearing under section 505(e) of the Federal Food, Drug,
and Cosmetic Act [21 U.S.C.A. § 355(e)] on a proposed
order of the Secretary to withdraw approval of an appli-
cation for such'drug under such section because the Sec-
retary has determined that the drug is less than effective
for some or all conditions of use prescribed, recom-
mended, or suggested in its labeling; and
(B) a biological product, other than a vaccine which-
(i) may only be dispensed upon prescription,
(ii) is licensed under section 262 [section 351 of the Pub-
lic Health Service Act], and
(iii) is produced at an establishment licensed under such
section to produce such product; and
(C) insulin certified under section 506 of the Federal Food,
Drug, and Cosmetic Act [21 U.S.C.A. § 356].
(3) Limiting definition. The term "covered outpatient drug" does
not include any drug, biological product, or insulin provided as part
of, or as incident to and in the same setting as, any of the following
(and for which payment may be made under this subehapter as part
of payment for the following and not as direct reimbursement for
the drug):
(A) Inpatient hospital services.
(B) Hospice services.
(C) Dental services, except that drugs for which the State plan
authorizes direct reimbursement to the dispensing dentist are
covered outpatient drugs.
(D) Physicians' services.
(E) Outpatient hospital services.
(F) Nursing facility services and services provided by an in-
termediate care facility for the mentally retarded.
(G) Other laboratory and x-ray services.
(H) Renal dialysis.
Such term also does not include any such drug or product for which
a National Drug Code number is not required by the Food and Drug
Administration or a drug or biological used for a medical indication
which is not a medically accepted indication. Any drug, biological
product, or insulin excluded from the definition of such term as a
result of this paragraph shall be treated as a covered outpatient drug
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for purposes of determining the best price (as defined in subsection
(c)(1)(C) of this section) for such drug, biological product, or insu-
lin.
(4) Nonprescription drugs. If a State plan for medical assistance
under this subchapter includes coverage of prescribed drugs as de-
scribed in section 1396d(a)(12) [section 1905(a)(12)] of this title
and permits coverage of drugs which may be sold without a pre-
scription (commonly referred to as "over-the-counter" drugs), if
they are prescribed by a physician (or other person authorized to
prescribe under State law), such a drug shall be regarded as a cov-
ered outpatient drug.
(5) Manufacturer. The term "manufacturer" means any entity
which is engaged in-
(A) the production, preparation, propagation, compounding,
conversion, or processing of prescription drug products, either
directly or indirectly by extraction from substances of natural
origin, or independently by means of chemical synthesis, or by
a combination of extraction and chemical synthesis, or
(B) in the packaging, repackaging, labeling, relabeling, or dis-
tribution of prescription drug products.
Such term does not include a wholesale distributor of drugs or a re-
tail pharmacy licensed under State law.
(6) Medically accepted indication. The term "medically accepted
indication" means any use for a covered outpatient drug which is
approved under the Federal Food, Drug, and Cosmetic Act [21
U.S.C.A. §§ 301 et seq.] or the use of which is supported by one or
more citations included or approved for inclusion in any of the
compendia described in subsection (g)(1)(B)(i) of this section.
(7) Multiple source drug; innovator multiple source drug; non-
innovator multiple source drug; single source drug.
(A) Defined.
(i) Multiple source drug. The term "multiple source
drug" means, with respect to a rebate period, a covered
outpatient drug (not including any drug described in para-
graph (5)) for which there are 2 or more drug products
which- (I) are rated as therapeutically equivalent (under
the Food and Drug Administration's most recent publica-
tion of "Approved Drug Products with Therapeutic
Equivalence Evaluations"), (H) except as provided in
subparagraph (B), are pharmaceutically equivalent and
bioequivalent, as defined in subparagraph (C) and as de-
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termined by the Food and Drug Administration, and
(III) are sold or marketed in the State during the period.
(ii) Innovator multiple source drug. The term "innova-
tor multiple source drug" means a multiple source drug
that was originally marketed under an original new drug
application approved by the Food and Drug Administra-
tion.
(iii) Noninnovator multiple source drug. The term
"noninnovator multiple source drug" means a multiple
source drug that is not an innovator multiple source drug.
(iv) Single source drug. The term "single source drug"
means a covered outpatient drug which is produced or
distributed under an original new drug application ap-
proved by the Food and Drug Administration, including a
drug product marketed by any cross-licensed producers or
distributors operating under the new drug application.
(B) Exception. Subparagraph (A)(i)(II) shall not apply if the
Food and Drug Administration changes by regulation the re-
quirement that, for purposes of the publication described in
subparagraph (A)(i)(I), in order for drug products to rated as
therapeutically equivalent, they must be pharmaceutically
equivalent and bioequivalent, as defined in subparagraph (C).
(C) Definitions. For purposes of this paragraph-
(i) drug products are pharmaceutically equivalent if the
products contain identical amounts of the same active
drug ingredient in the same dosage form and meet com-
pendial or other applicable standards of strength, quality,
purity, and identity;
(ii) drugs are bioequivalent if they do not present a known
or potential bioequivalence problem, or, if they do present
such a problem, they are shown to meet an appropriate
standard of bioequivalence; and
(iii) a drug product is considered to be sold or marketed in
a State if it appears in a published national listing of aver-
age wholesale prices selected by the Secretary, provided
that the listed product is generally available to the public
through retail pharmacies in that State.
(8) Rebate period. The term "rebate period" means, with respect to
an agreement under subsection (a) of this section, a calendar quarter
or other period specified by the Secretary with respect to the pay-
ment of rebates under such agreement.
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(9) State agency. The term "State agency" means the agency designated
under section 1396a(a)(5) [section 1902(a)(5)] of this title to administer
or supervise the administration of the State plan for medical assistance.
42 U.S.C.A. § 1396r-8 (West Supp. 2000)
